

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 May 2003 (30.05.2003)

PCT

(10) International Publication Number
WO 03/043572 A2

- (51) International Patent Classification⁷: A61K SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: PCT/US02/36758
- (22) International Filing Date:
14 November 2002 (14.11.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/332,412 16 November 2001 (16.11.2001) US
- (71) Applicant: 3M INNOVATIVE PROPERTIES COMPANY [US/US]; 3M Center, Post Office Box 33427, Saint Paul, MN 55133-3427 (US).
- (72) Inventors: GORDEN, Keith, B.; Post Office Box 33427, Saint Paul, MN 55133-3427 (US). QIU, Xiaohong; Post Office Box 33427, Saint Paul, MN 55133-3427 (US). TOMAI, Mark, A.; Post Office Box 33427, Saint Paul, MN 55133-3427 (US). VASILAKOS, John, P.; Post Office Box 33427, Saint Paul, MN 55133-3427 (US).
- (74) Agents: GRAM, Christopher, D. et al.; Office of Intellectual Property Counsel, Post Office Box 33427, Saint Paul, MN 55133-3427 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KB, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- Published:**
- without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR PATHWAYS

(57) Abstract: Methods for identifying a compound that activates a TLR-mediated cellular signaling pathway is disclosed. The method includes (a) exposing a TLR-positive cell culture to a test compound and measuring a TLR-mediated cellular response; (b) exposing a TLR-negative cell culture to a test compound and measuring a TLR-mediated cellular response; and (c) identifying the test compound as an IRM if the cellular response in the TLR-positive cell culture is greater than the cellular response of the TLR-negative cell culture. Methods of eliciting a TLR-mediated cellular response are also disclosed. Such methods include administration of an IRM compound to an IRM-responsive cell so that the IRM compounds affects at least one TLR-mediate cellular signaling pathway.

WO 03/043572 A2

METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR PATHWAYS

Background of the Invention

5 Immune response modifiers ("IRMs") include compounds that possess potent immunostimulating activity including but not limited to antiviral and antitumor activity. Certain IRMs effect their immunostimulatory activity by inducing the production and secretion of cytokines such as, e.g., IFN- α , TNF- α , IL-1, IL-6, IL-8, IL-10, IL-12, MIP-1, and MCP-1. Certain IRMs are small organic molecules such as those disclosed in, for
10 example, U.S. Patent Nos. 4,689,338; 4,929,624; 5,266,575; 5,268,376; 5,352,784; 5,389,640; 5,482,936; 5,494,916; 6,110,929; 6,194,425; 4,988,815; 5,175,296; 5,367,076; 5,395,937; 5,693,811; 5,741,908; 5,238,944; 5,939,090; 6,245,776; 6,039,969; 6,083,969; 6,245,776; 6,331,539; and 6,376,669; and PCT Publications WO 00/76505; WO 00/76518; WO 02/46188, WO 02/46189; WO 02/46190; WO 02/46191; WO 02/46192;
15 WO 02/46193; and WO 02/46194.

 Additional small molecule IRMs include purine derivatives (such as those described in U.S. Patent Nos. 6,376,50 and 6,028,076), small heterocyclic compounds (such as those described in U.S. Patent No. 6,329,381), and amide derivatives (such as those described in U.S. Patent No. 6,069,149).

20 Other IRMs include large biological molecules such as oligonucleotide sequences. Some IRM oligonucleotide sequences contain cytosine-guanine dinucleotides (CpG) and are described, for example, in U.S. Patent Nos. 6,199,388; 6,207,646; 6,239,116; 6,339,068; and 6,406,705. Other IRM nucleotide sequences lack CpG and are described, for example, in International Patent Publication No. WO 00/75304.

25 By stimulating certain aspects of the immune system, as well as suppressing other aspects (see, e.g., U.S. Patent Nos. 6,039,969 and 6,200,592), IRMs may be used to treat many diseases. For example, the small molecule IRM imiquimod is useful for the treatment of external genital and perianal warts caused by human papillomavirus [Tomai *et al.*, *Antiviral Research* 28(3): 253-264 (1995)]. Examples of other diseases that may be
30 treated using IRM compounds include, but are not limited to, basal cell carcinoma, eczema, essential thrombocythaemia, hepatitis B, multiple sclerosis, neoplastic diseases, psoriasis, rheumatoid arthritis, type I herpes simplex, and type II herpes simplex.

IRM compounds can modulate cell-mediated immunity by inducing secretion of certain immune system regulator molecules such as cytokines. For example, cytokines that are induced by imiquimod or resiquimod include but are not limited to IFN- α , TNF- α , IL-1, IL-6, IL-8, IL-10, IL-12, MIP-1, and MCP-1 [see, e.g., Tomai et al, Antiviral Research 28(3): 253-64 (1995); Megyeri et al., Molecular and Cellular Biology 15(4): 2207-18 (1995)].

IRM compounds also can modulate humoral immunity by stimulating antibody production by B cells. Further, various IRMs have been shown to be useful as vaccine adjuvants (see, e.g., U.S. Pat. Nos. 6,083,505 and 6,406,705).

Elucidating and differentiating the biological mechanism and signaling pathways underlying the activities of the various IRM compounds would greatly aid in the identification and development of new IRM compounds and methods of treatment using these compounds.

Summary of the Invention

It has been found that many IRM compounds act through Toll-Like Receptor (TLR) pathways, including pathways mediated by TLR6 and TLR7.

The present invention provides methods of identifying an IRM compound that activates a TLR-mediated cellular signaling pathway. The method includes (a) exposing a TLR-positive cell culture to a test compound and measuring a TLR-mediated cellular response; (b) exposing a TLR-negative cell culture to a test compound and measuring a TLR-mediated cellular response; and (c) identifying the test compound as an IRM if the cellular response in the TLR-positive cell culture is greater than the cellular response of the TLR-negative cell culture. In certain embodiments, the methods can identify agonists of TLR6. In other embodiments, the methods can identify agonists of TLR7.

In another aspect, the present invention provides methods of identifying an IRM antagonist that inhibits a TLR-mediated cellular signaling pathway. The method includes (a) exposing a first IRM-responsive cell culture to an IRM compound and measuring a TLR-mediated cellular response; (b) exposing a second IRM-responsive cell culture to an IRM compound and a test compound, and measuring a TLR-mediated cellular response; and (c) identifying the test compound as an IRM antagonist if the cellular response in the first cell culture is greater than the cellular response of the second cell culture.

In another aspect, the present invention provides compounds identified as TLR agonists, and pharmaceutical compositions that include compounds identified as TLR agonists or pharmaceutically acceptable salts thereof.

5 In another aspect, the present invention provides a method of eliciting a TLR-mediated cellular response in a cell that expresses a TLR. The method includes (a) selecting a compound identified as a TLR agonist; and (2) administering to the cell the compound in an amount that affects at least one TLR-mediated cellular signaling pathway. In certain embodiments, the methods include selecting and administering a TLR6 agonist. In other embodiments, the methods include selecting and administering a TLR7 agonist.

10 In yet another aspect, the present invention provides method of treating an organism having a condition treatable by modulating a TLR-mediated cellular response. The method includes (a) selecting a compound identified as a TLR agonist; and (b) administering to the organism the compound in an amount effective to modulate a TLR-mediated cellular signaling pathway. In certain embodiments, the methods include
15 selecting and administering a TLR6 agonist. In other embodiments, the methods include selecting and administering a TLR7 agonist.

Various other features and advantages of the present invention should become readily apparent with reference to the following detailed description, examples, claims and
20 appended drawings. In several places throughout the specification, guidance is provided through lists of examples. In each instance, the recited list serves only as a representative group and should not be interpreted as an exclusive list.

Detailed Description of Illustrative Embodiments of the Invention

25 The present invention provides methods of detecting compounds that act as agonists for TLRs. The present invention also provides methods of identifying compounds that act as antagonists of TLRs. A compound identified as a TLR6 agonist or a TLR7 agonist may be employed to elicit a TLR6-mediated or a TLR7-mediated cellular response, respectively. Such cellular responses include but are not limited to altering
30 cytokine production, NF- κ B activation, and expression of co-stimulatory markers. Accordingly, the present invention also provides methods of treating an organism having a condition treatable by modulating a TLR6-mediated or TLR7-mediated cellular response.

Such conditions include but are not limited to neoplastic diseases, Th1-mediated diseases, Th2-mediated diseases, and infectious diseases (e.g., viral diseases, bacterial diseases, fungal diseases, parasitic diseases, protozoal diseases, prion-mediated diseases, and the like).

5 For purposes of this invention, the following terms shall have the meanings set forth.

 “Agonist” refers to a compound that can combine with a receptor (e.g., a TLR) to produce a cellular response. An agonist may be a ligand that directly binds to the receptor. Alternatively, an agonist may combine with a receptor indirectly by, for example, (a)
10 forming a complex with another molecule that directly binds to the receptor, or (b) otherwise resulting in the modification of another compound so that the other compound directly binds to the receptor. An agonist may be referred to as an agonist of a particular TLR (e.g., a TLR6 agonist).

 “Cellular signaling pathway” refers to a cascade of biochemical activity that
15 biochemically links an agonist-receptor interaction with a cellular response to the agonist-receptor binding (e.g., cytokine production).

 “Dominant negative” refers to a variant of a naturally occurring protein in which the variant has been altered to possess at least one natural activity, but lack at least one other natural activity. As a nonlimiting example, a dominant negative variant of a receptor
20 protein may bind to its normal binding partner (e.g., a ligand) but fail to promote a second activity that normally results from the receptor-ligand binding (e.g., relay a cellular signal).

 “Express/expression” refers to the ability of a cell to transcribe a structural gene, resulting in an mRNA, then translating the mRNA to form a protein that provides a
25 detectable biological function to the cell.

 “Inhibit” refers to any measurable reduction of biological activity. Thus, as used herein, “inhibit” or “inhibition” may be referred to as a percentage of a normal level of activity.

 “Imiquimod” refers to 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine.
30 “IRM antagonist” refers to any compound that inhibits biological activity that normally results from exposing an IRM-responsive cell to an IRM compound.

“IRM compound” refers to a compound that alters the level of one or more immune regulatory molecules, e.g., cytokines or co-stimulatory markers, when administered to an IRM-responsive cell. Representative IRM compounds include the small organic molecules, purine derivatives, small heterocyclic compounds, amide derivatives, and oligonucleotide sequences described above.

“IRM-responsive cell” refers to any cell that exhibits a cellular response when exposed to an IRM compound.

“Resiquimod” refers to 4-amino-2-ethoxymethyl- α,α -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol.

“TLR-mediated” refers to a biological or biochemical activity that results from TLR function. A particular biological or biochemical activity may be referred to as mediated by a particular TLR (e.g., “TLR6-mediated” or “TLR7-mediated”).

“TLR-positive” refers to a cell culture selected to provide greater detectable function of a particular TLR (e.g., “TLR6-positive” or “TLR7-positive”) than a corresponding TLR-negative cell culture (e.g., “TLR6-negative” or “TLR7-negative”). A TLR-positive cell culture may exhibit greater than normal TLR function, e.g., overexpression of TLR function compared to a TLR-negative cell culture exhibiting generally normal TLR function. Alternatively, a TLR-positive cell culture may exhibit generally normal or less than normal TLR function, e.g., a cell culture exhibiting generally normal TLR function compared to a TLR-negative cell culture exhibiting inhibited TLR function.

“TLR-negative” refers to a cell culture selected to provide less detectable function of a particular TLR (e.g., “TLR6-negative” or “TLR7-negative”) than a corresponding TLR-positive cell culture (e.g., “TLR6-positive” or “TLR7-positive”). A TLR-negative cell culture may exhibit less than normal TLR function, e.g., inhibited TLR function compared to a TLR-positive cell culture exhibiting generally normal TLR function. Alternatively, a TLR-negative cell culture may exhibit generally normal or greater than normal TLR function, e.g., a cell culture exhibiting generally normal TLR function compared to a TLR-positive cell culture exhibiting greater than normal TLR function.

Certain cells of the immune system (e.g., antigen presenting cells, or “APCs”) recognize foreign antigens, some of which potentially may be harmful to the host, and trigger an immune response against the antigen. Toll-Like Receptors (TLRs) are a family

of immune system receptors that permit cells of the immune system to recognize specific molecular patterns presented by foreign antigens. The molecular patterns are commonly termed pathogen-associated molecular patterns ("PAMPs"). The TLRs include an extracellular domain that contains a leucine-rich domain and a cytoplasmic domain that resembles the cytoplasmic domain of the interleukin-1 receptor.

Activation of the various TLRs induces a range of biological effects including the secretion of cytokines and antimicrobial peptides. Cytokines are important immune system regulatory molecules and include, but are not limited to, TNF- α , IFN- α , and the interleukins. Cytokines act upon cellular receptors and regulate such diverse cellular activities as cell growth, cell differentiation, cell death, the inflammatory process, and cell migration.

The discovery of different TLRs has led to the identification of signaling pathways that connect the receptors to the biological effects of their activation. The cytoplasmic protein MyD88 has been identified as one member of cellular signaling pathways that also include various TLRs. The MyD88 protein has an IL-1 receptor domain similar to that of the cytoplasmic domain of the TLRs. The IL-1 receptor domain of the MyD88 and the cytoplasmic TLR domain interact when the TLR binds to a ligand and, in turn, cause other cytoplasmic proteins (e.g., IRAK and TRAF6) to interact. The signal cascade that begins with an agonist binding to a TLR and is relayed through IRAK and TRAF6 eventually activates NF- κ B, which stimulates transcription of various genes including those encoding cytokines such as TNF- α , IL-6, and IL-12.

Many IRM compounds share a number of cellular activities, many of which are conserved across species, e.g., upregulation of co-stimulatory markers, induction of pro-inflammatory cytokines in monocyte/macrophage cells, and activation of transcriptional regulators NF- κ B and AP-1. Identifying TLR agonists, including but not limited to IRM compounds, also may identify compounds having prophylactic or therapeutic utility for certain conditions that are treatable by inducing an immune response through one or more TLRs.

A dominant-negative variant of a TLR may be employed to identify agonists of the TLRs. Table 2 shows how the use of a dominant negative variant of TLR6 (TLR6DN) or TLR7 (TLR7DN) may be used to identify an agonist of TLR6 or TLR7, respectively. Two sets of THP-1 cells were transfected with a vector into which construct encoding a

dominant-negative variant of a TLR (generally, TLRDN) had been cloned. One set of cells was transfected with vector including a TLR6DN construct; the other set was transfected with vector including a TLR7DN construct. THP-1 cells are human monocyte cells derived from acute monocytic leukemia tissue and are known to exhibit increased TNF- α production upon stimulation with TLR agonists such as zymosan (a known agonist of TLR6) or LPS (a known agonist of TLR4). As a control, THP-1 cells were also transfected with vector lacking a dominant-negative TLR construct.

The transfectants were cultured and exposed to various stimuli: LPS, zymosan, and resiquimod, an IRM compound. The effect of the dominant-negative variants was assessed by measuring the extent to which TNF- α production, upon exposure to a stimulus, was inhibited in cells transfected with a TLRDN compared to cells transfected with a control vector. TLR6DN inhibited TNF- α production upon stimulation with zymosan - a known TLR6 agonist - and resiquimod, but did not materially inhibit TNF- α production when stimulated with the TLR4 agonist LPS. TLR7DN inhibited TNF- α production upon stimulation with LPS and resiquimod, but did not materially inhibit TNF- α production upon stimulation with zymosan.

Table 3 illustrates that the effect is not specific to the host cell type. The TLR6DN construct was transfected into RAW 264.7 cells, a mouse macrophage cell line known to produce TNF- α upon stimulation with a TLR agonist, such as zymosan or LPS. As in the THP-1 cells, TNF- α production by TLR6DN-transfected RAW 264.7 cells was inhibited to a much greater extent when upon stimulation with zymosan or resiquimod than when stimulated with the TLR7 agonist LPS.

Thus, a dominant negative variant of a TLR may be employed to identify an agonist of the TLR. The use of TLR6DN can be used to confirm that a known TLR6 agonist, such as zymosan, acts through TLR6. TLR6DN also can be used to identify additional TLR6 agonists, such as IRM compounds including but not limited to resiquimod. Similarly, TLR7DN may be used to confirm that a known TLR7 agonist acts through TLR7. TLR7DN also can be used to identify additional TLR7 agonists, such as IRM compounds including but not limited to resiquimod. One skilled in the art will recognize that a broad range of potential IRM compounds may be screened in this fashion to identify agonists of any TLR for which a TLRDN can be constructed and expressed.

A TLR agonist also can be identified by employing TLR-specific antibodies that neutralize TLR function. Table 4 shows that anti-TLR6 antibodies can be used to specifically inhibit TLR6-mediated TNF- α production. When RAW 264.7 cells are preincubated with anti-TLR6 antibodies and then incubated with various stimuli, the TNF- α production induced by known TLR6 agonists peptidoglycan and zymosan is inhibited by the antibodies to a greater extent than TNF- α production in response to the TLR4 agonist LPS. In addition, stimulation of TNF- α production by various IRM compounds also is strongly inhibited by presence of the anti-TLR6 antibodies, thereby identifying these IRM compounds as TLR6 agonists.

Overexpression of a TLR also can be used to identify a TLR agonist. Table 5 shows that overexpression of TLR6 or TLR7 can make RAW 264.7 cells more sensitive to IRM induction of TNF- α production. Specifically, RAW 264.7 cells can be transfected with a vector that encodes a TLR (e.g., TLR6 or TLR7) expressed from a strong eukaryotic promoter. When incubated with various concentrations of resiquimod, the RAW 264.7 cells can exhibit increased stimulation of TNF- α production compared to resiquimod-stimulated untransfected RAW 264.7 cells. For both cultures of TLR-overexpression transfectants, the extent to which TNF- α production is stimulated decreases as the concentration of resiquimod increases (i.e., the dose-response curve was shifted lower). Thus, resiquimod is an agonist of each of TLR6 and TLR7. The data also show that, in a given cell, the induction of TNF- α production by resiquimod is limited by the extent to which the cell expresses TLR.

Table 6 shows that a broad spectrum of IRM compounds can induce NF- κ B activation through TLR7. HEK293 cells, derived from human embryonic kidney cells, may be co-transfected with (1) either a control vector or a vector construct including human TLR7, and (2) an NF- κ B-luciferase reporter. The NF- κ B-luciferase reporter provides a luciferase signal upon NF- κ B activation in a transfected cell. Thus, TLR7-mediated NF- κ B activity can be detected by exposing the cells transfected with vector and the cells transfected with the TLR7 construct to an IRM compound, then comparing the luciferase signal of the vector-transfected cells with the luciferase signal of the cells transfected with the TLR7 construct.

Table 6 shows that various IRM compounds stimulate NF- κ B activity in transfected cells to varying degrees, ranging up to more than an 12-fold increase in NF- κ B activation over cells transfected with only vector.

5 **Assays**

The present invention provides assays that can be used to discover new IRM compounds that can activate or inhibit at least one Toll pathway. The assays described below are exemplary embodiments of the invention and are not intended to represent the limits of the invention.

10 The present invention provides methods for identifying an IRM compound that activates at least one Toll pathway, wherein the methods include determining whether a particular compound elicits a TLR-mediated cellular response. One way this can be done is by eliminating or reducing the activity of at least one TLR in a cell and measuring the resulting effect of eliminating the TLR on at least one TLR-mediated cellular response.

15 In some embodiments, the methods of the present invention include transfecting an IRM-responsive cell with a dominant-negative variant of a TLR to eliminate or to measurably reduce TLR-mediated activity upon exposure of the transfected cell to an IRM compounds.

A dominant-negative variant (TLRDN) can be constructed in various ways. In
20 some embodiments, a TLRDN can be made by altering the cytoplasmic domain of the protein, thereby disrupting binding between the TLR and its cytoplasmic binding partners. In other embodiments, the TLR may be altered to disrupt TLR-agonist binding. Regardless of the specific change made in the TLR, a dominant-negative variant will be unable to relay at least one TLR-mediated cellular signal when exposed to a TLR agonist.

25 A mutation resulting in a TLRDN may be a point mutation, a deletion or an insertion. A deletion or insertion may be of any size. In some of these embodiments, the mutation can be non-conservative. In other embodiments, the mutation can be conservative. In yet other embodiments, the mutation at the DNA level may form a stop codon, resulting in a truncated protein. Alternatively, the mutation may cause a shift in
30 the reading frame that changes the amino acid sequence downstream from the frameshift mutation.

One method of identifying an IRM compound that activates a TLR-mediated cell signaling pathway according to the invention includes exposing a TLR-positive cell culture to a test compound and measuring a TLR-mediated cellular response; exposing a TLR-negative cell culture to a test compound and measuring a TLR-mediated cellular response; and identifying the compound as an IRM compound if the cellular response in the TLR-positive cell culture is greater than the cellular response of the TLR-negative cell culture.

The step of exposing a TLR-positive cell culture to a test compound and measuring a TLR-mediated cellular response may include exposing a control IRM-responsive cell culture (e.g., cells transfected with a null vector) to the test compound, measuring the TLR-mediated cellular response of the control culture, and comparing the cellular response of the TLR-positive test culture to the cellular response of the control culture. Similarly, the step of exposing a TLR-negative cell culture to a test compound and measuring a TLR-mediated cellular response may include exposing a control IRM-responsive cell culture to the test compound, measuring the TLR-mediated cellular response in the control culture, and comparing the cellular response of the TLR-negative test culture to the cellular response of the control culture. However, with experience, one skilled in the art may develop sufficient familiarity with a particular assay that explicit use of controls may not always be necessary to identify an IRM compound using the methods of the present invention.

The method may be designed to identify compounds that activate any particular TLR. Routine methods may be employed to produce a TLR-positive cell culture, a TLR-negative cell culture, or both for any particular TLR. In some embodiments, the method may be designed to identify a compound that activates a TLR6-mediated cell signaling pathway. In other embodiments, the method may be designed to identify a compound that activates a TLR7-mediated cell signaling pathway.

In some embodiments, the TLR-positive cell culture may include cells that provide a greater than normal IRM-mediated cellular response. For example, the TLR-positive cell culture may include cells that have been genetically modified, such as by transfection, to provide a greater than normal IRM-mediated response when stimulated with an IRM. Such genetic modifications may include providing additional copies of TLR structural genes so that transfected cells overexpress the TLR. Additionally, overexpression of a

TLR may result from cloning the relevant TLR gene under the control of one or more strong transcriptional regulatory sequences.

5 The TLR-positive cell culture may include transfected cells that overexpress TLR6. Alternatively, the TLR-positive cell culture may include cells transfected to overexpress TLR7. Cells that express or overexpress a TLR can be made by various standard techniques (See, e.g., Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (2001)). In embodiments in which the TLR-positive cell culture provides a greater than normal TLR-mediated cellular response, the TLR-negative cell culture may include cells that provide a generally normal level TLR-mediated cellular response.
10 Alternatively, the TLR-negative cell culture may include cells that provide a lower than normal TLR-mediated cellular response.

In other embodiments, the TLR-positive cell culture may include cells that provide a generally normal TLR-mediated cellular response. In such embodiments, the TLR-negative cell culture includes cells that provide a lower than normal TLR-mediated
15 cellular response. In such embodiments, the TLR-negative cell culture may include cells that have been genetically modified to provide the lower than normal TLR-mediated response when stimulated with an IRM. For example, the TLR-negative cell culture may include cells that have been transfected with a vector that encodes a dominant-negative TLR variant including but not limited to TLR6DN and TLR7DN. In other embodiments,
20 the TLR-negative cell culture may include cells that have been transfected with vectors that include antisense constructs of a TLR to at least partially inhibit expression of the TLR. See, e.g., Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (2001).

Alternatively, the TLR-negative cell culture may include one or more inhibitory
25 components that interfere with either (1) binding of the test compound with the TLR, or (2) the ability of the TLR to relay a cellular signal after binding to an agonist (i.e., the test compound). For example, the TLR-negative cell culture may include an antibody that specifically binds to the TLR (an anti-TLR antibody, generally), thereby at least partially inhibiting the TLR-mediated cellular response. The generation of an antibody that
30 specifically binds to a particular target is considered routine to one skilled in the art. Thus, an anti-TLR antibody can be used to provide a TLR-negative cell culture according to the methods of the present invention. In certain embodiments, however, an anti-TLR6

antibody may be used to provide a TLR6-negative cell culture. The anti-TLR antibody may be added to the cell culture prior to the test compound or may be added with the test compound. The anti-TLR antibody may be polyclonal or monoclonal. The final concentration of antibody in the cell culture may range from about 0.01 µg/ml to about 100 µg/ml. The cells of the cell culture may be pre-incubated with the anti-TLR antibody from about 0 minutes to about 48 hours prior to addition of the test compound.

In some embodiments, the TLR-mediated cellular response may include production of at least one cytokine including, but not limited to, TNF-α, IFN-α, IL-1, IL-6, IL-8, IL-10, IL-12, MIP-1, MCP-1, or any combination thereof. In other embodiments, the TLR-mediated cellular response may include activation of NF-κB. In still other embodiments, the TLR-mediated cellular response may include production of one or more co-stimulatory markers including, but not limited to, CD40, CD80, CD86 and CCR7.

Yet other embodiments of the invention provide methods for identifying IRM compounds that activate at least one TLR-mediated cellular signaling pathway, wherein the methods comprise the use of TLR deficient mice (knockout mice). With knockout mice, the IRM compounds can be identified by their effects at the whole organism level. Techniques for generating such mice are well-established in the art, and one of skill in the art would readily be able to create such mice See, e.g., Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (2001). Alternatively, specific knockout mice can be ordered custom-made from various commercial services such as inGenious Targeting Laboratory, Inc. (Stony Brook, NY).

In certain embodiments directed to using TLR6 and/or TLR7 knockout mice, the compound may be administered to the mouse and, after a suitable incubation period, the effects on the mouse may be analyzed. The effects may be analyzed, in certain of these embodiments, by measuring cytokine levels from the blood of the treated mice. In other embodiments, certain cell types may be isolated from the treated mice and the production of cytokines or NF-κB activation determined by known methods.

Typically, cells in which TLR6 and/or TLR7 expression has been at least partially inhibited will exhibit at least a 20% reduction in the extent to which administration of the IRM compound stimulates IRM-mediated activity (e.g., cytokine production or NF-κB activation) compared to untransfected cells stimulated with the same concentration of test compound. In certain embodiments the cells may exhibit at least a 50% reduction in the

extent to which administration of an IRM stimulates IRM-mediated activity. In other embodiments, at least an 80% reduction is observed.

As indicated above, the methods of the present invention may be employed to identify agonists of any desired TLR. One of ordinary skill in the art can create a TLR-
5 positive cell culture or a TLR-negative cell culture for any particular TLR using the methods described above.

In one embodiment, the method may be designed to identify an agonist of TLR6 by employing a TLR6 overexpression cell culture as a TLR6-positive cell culture, an unmodified cell culture as a TLR6-negative cell culture, and measure a TLR6-mediated
10 cellular response in each cell culture after stimulation with a test compound. In an alternative embodiment identifying a TLR6 agonist, the method may employ an unmodified cell culture as a TLR6-positive cell culture, and either a TLR6DN cell culture or a cell culture that includes anti-TLR6 antibodies as the TLR6-negative cell culture.

In another embodiment, the method may be designed to identify an agonist of
15 TLR7 by employing a TLR7 overexpression cell culture as a TLR7-positive cell culture, an unmodified cell culture as a TLR7-negative cell culture, and measure a TLR7-mediated cellular response in each cell culture after stimulation with a test compound. In an alternative embodiment identifying a TLR7 agonist, the method may employ an unmodified cell culture as a TLR7-positive cell culture, and either a TLR7DN cell culture
20 or a cell culture that includes anti-TLR7 antibodies as the TLR7-negative cell culture.

The present invention also provides compounds identified as IRM compounds based on the character of the compound as an agonist of a TLR. In some embodiments, the compounds of the present invention are agonists of TLR6. In other embodiments, the compounds are agonists of TLR7. The present invention also provides pharmaceutical
25 compositions that include a compound that is a TLR agonist, or pharmaceutically acceptable salts of TLR agonist compounds. Pharmaceutical compositions may include one or more additional components including but not limited to a pharmaceutically acceptable vehicle, one or more adjuvants, one or more pharmaceutically active compounds (i.e., the TLR agonist may serve as an adjuvant), and the like.

30 The present invention also provides methods of identifying an IRM antagonist that inhibits a TLR-mediated cellular signaling pathway. Such methods include exposing a first IRM-responsive cell culture to an IRM compound and measuring an IRM-mediated

cellular response; exposing a second IRM-responsive cell culture to an IRM compound and a test compound and measuring an IRM-mediated cellular response; and identifying the test compound as an IRM antagonist if the cellular response in the first cell culture is greater than the cellular response in the second cell culture.

5 The IRM-responsive cell culture may include cells that naturally express one or more TLRs. Alternatively, the IRM-responsive cell culture may include cells of any of the IRM-positive cell cultures described above. An antagonist of IRM that is an agonist of a particular TLR may be identified by employing a particular TLR-positive cell culture in the present method. For example, an antagonist of a TLR7 agonist IRM may be identified
10 using a TLR7-positive cell culture such as a cell culture including cells designed to overexpress TLR7 when exposed to an IRM compound.

 As with the identification methods described above, the identification of IRM antagonist compounds may include the use of a control cell culture against which the TLR-mediated cellular response of the first IRM-responsive cell culture and second IRM-
15 responsive cell culture are compared. However, again similar to the methods described above, one skilled in the art may develop sufficient familiarity with the assay that running a control for each assay may become unnecessary.

 The concentration of the test compound being assayed by the above methods may range from about 0.001 μM to about 100 μM . The cell culture may be incubated with the
20 test compound from about 10 minutes to about 24 hours. The density of cells incubated with the compound to be tested may be from 1×10^4 to 1×10^7 cells/ml.

 In some embodiments, cytokine levels are determined using a commercially available ELISA assay. In other embodiments, cytokine levels are determined using such techniques as, but not limited to, antibody detection and quantitation (*e.g.*, flow cytometry,
25 western blotting, immunohisto/cytochemistry), and bioassays (*e.g.*, L929 cytotoxicity assay where the amount of cell death is directly proportional to the amount of TNF- α in the sample). See, *e.g.*, Current Protocols in Immunology, John Wiley and Sons, Inc. (2001).

 The cytokine that is assayed can be TNF- α . TNF- α levels can be determined by
30 ELISA assay. As the minimum level of detection for this assay is 40-80 pg/ml, the test is considered suspect if the level of TNF- α following stimulation is under 100 pg/ml, and the experiment should be redone.

IRM-responsive cells used in the above-described methods may be from plants or from animals, particularly vertebrate organisms. The IRM-responsive cells may be from mammals such as, but not limited to, human, rodent, dog, cat, sheep, cow, or rabbit. These IRM-responsive cells may include, but are not limited to, monocytes, macrophages, Langerhans cells, dendritic cells, and B-cells. The IRM-responsive cells may be from established cell lines such as RAW 264.7, THP-1, or HEK293.

The TLR genes utilized in the methods may derive from a variety of plant and animal sources including mammals such as, but not limited to, human, rodent, dog, cat, sheep, cow, or rabbit.

The expression of a particular TLRs in cells employed in the methods of the present invention may result from natural gene expression in the cells. Cells that naturally express TLRs include, but are not limited to, RAW 264.7 cells, THP-1 cells, HEK293 cells, monocytes, dendritic cells, macrophages, and B lymphocytes. Alternatively, the expression of a particular TLR may result from the genetic modification of cells. The cells so modified may naturally express or they may lack natural expression of the particular TLR. The expression of a particular TLR in cells employed in the methods of the present invention may be at a level higher than, lower than, similar to, or equal to the normal level of expression of the particular TLR in the particular line of cells.

Many different cytokines and/or co-stimulatory markers can be assayed in the methods described above. Suitable measurable cytokines include, but are not limited to, TNF- α , IFN- α , IL-1, IL-6, IL-8, IL-10, IL-12, MIP-1, and MCP-1. Suitable measurable co-stimulatory markers include, but are not limited to, CD40, CD80, CD86 and CCR7.

A compound identified as a TLR agonist or a TLR antagonist by any of the methods described above, or identified by any other method, may be employed to elicit TLR-mediated cellular responses. As used herein, the term "elicit" includes upregulation or downregulation of a particular cellular response. A compound identified as a TLR agonist or a TLR antagonist by any of the methods described above, or identified by any other method, also may be used to treat an organism having a condition treatable by modulating a TLR-mediated cellular response.

Methods for Eliciting TLR-Mediated Cellular Responses

The present invention also provides methods of eliciting a TLR-mediated cellular response by manipulating a TLR-mediated signaling pathway. Certain TLR-mediated cellular responses elicited by the methods of the present invention include induction of cytokine production; other cellular responses include inhibiting production of certain cytokines.

The invention provides a method of eliciting at least one TLR-mediated cellular response in an IRM-responsive cell by administering to the IRM-responsive cells an IRM compound that affects at least one TLR-mediated cellular signaling pathway.

The IRM compound may be any suitable IRM compound. In certain embodiments, suitable IRM compounds include but are not limited to imidazopyridine amines; imidazonaphthyridine amines; imidazotetrahydronaphthyridine amines; thiazoloquinoline amines; thiazolonaphthyridine amines; imidazothienopyridines; oxazoloquinoline amines; or imidazoquinoline amines including but not limited to 1,2-bridged imidazoquinoline amines, sulfonamido-substituted imidazoquinoline amines; urea-substituted imidazoquinoline amines; or heteroaryl ether-substituted imidazoquinoline amines. Specifically, suitable IRM compounds include but are not limited to *N*-[4-(4-amino-2-butyl-6,7-dimethyl-1*H*-imidazo[4,5-*c*]pyridin-1-yl)butyl]methanesulfonamide; *N*-[4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide; 1-(2-[3-(3-pyridyl)propoxy]ethyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine; 4-amino-2-butyl- α,α -dimethyl-1*H*-imidazo[4,5-*d*]thieno[3,2-*b*]pyridine-1-ethanol; 2-butyl-6,7,8,9-tetrahydro-1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*][1,5]naphthyridin-4-amine; *N*-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide; or 4-amino-2-(ethoxymethyl)- α,α -dimethyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-1-ethanol hydrate.

Suitable IRM compounds also include the purine derivatives, small heterocyclic compounds, amide derivatives, and oligonucleotide sequences described above. Alternatively, the IRM molecules employed in some methods according to the present invention may include compounds subsequently identified as TLR agonists.

In some embodiments, the TLR-mediated cellular response may include production of at least one cytokine including, but not limited to, TNF- α , IFN- α , IL-1, IL-6, IL-8, IL-10, IL-12, MIP-1, MCP-1, or any combination thereof. In other embodiments, the TLR-mediated cellular response may include activation of NF- κ B. In still other

embodiments, the TLR-mediated cellular response may include production of one or more co-stimulatory markers including, but not limited to, CD40, CD80, CD86 and CCR7. Suitable IRM-responsive cells include, but are not limited to, monocytes, macrophages, Langerhans cells, dendritic cells, and B lymphocytes.

5

Treatments

The activation of a TLR pathway of an organism may result in increased or decreased production of at least one cytokine. Because the ability to control cytokine levels can be useful in the treatment of cytokine-related conditions, the present invention also provides methods of treating these conditions. It is possible that in certain
10 embodiments, production of one or more cytokines will be induced, while the production of one or more other cytokines will be inhibited.

Therefore, the present invention provides a method of treating an organism having a condition treatable by modulating a TLR-mediated cellular response. The method
15 includes administering to the organism an IRM compound that activates a TLR-mediated cellular signaling pathway, provided that the IRM compound. The IRM compound may be an agonist of any suitable TLR (e.g., TLR6 or TLR7).

Activation of a TLR pathway may be useful in treating a variety of disorders that are responsive to cytokines. Activation of a TLR pathway according to the methods of the
20 present invention may have an effect on the acquired immune response. For example, the production of the T helper type 2 (Th2) cytokines IL-4, IL-5 and IL-13 are inhibited upon activation of the TLR pathway. This activity indicates that the methods of the present invention may provide treatment of conditions where upregulation of the Th1 response and/or down regulation of the Th2 response is desired. Such conditions include but are
25 not limited to atopic diseases (e.g., atopic dermatitis, asthma, allergy, allergic rhinitis) and systemic lupus erythematosus. The methods of the present invention also may provide vaccine adjuvants for cell mediated immunity and treatments for recurrent fungal diseases and chlamydia.

Agents that activate the TLR pathway are expected to be particularly useful in the
30 treatment of viral diseases and tumors. Their immunomodulating activity suggests that such agents are useful in treating diseases including, but not limited to, viral diseases including genital warts, common warts, plantar warts, Hepatitis B, Hepatitis C, Herpes

Simplex Virus Type I and Type II, rhinovirus, adenovirus, influenza, para-influenza, molluscum contagiosum, varriola major, HIV, CMV, VZV; intraepithelial neoplasias such as cervical intraepithelial neoplasia, human papillomavirus (HPV), and associated neoplasias; fungal diseases, e.g., candida, aspergillus, onychomycosis, tinea pedia, and
5 cryptococcal meningitis; neoplastic diseases, e.g., basal cell carcinoma, hairy cell leukemia, Kaposi's sarcoma, renal cell carcinoma, squamous cell carcinoma, myelogenous leukemia, multiple myeloma, melanoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, and other cancers; parasitic diseases, e.g., pneumocystis carinii, cryptosporidiosis, histoplasmosis, toxoplasmosis, trypanosome infection, and
10 leishmaniasis; and bacterial infections, e.g., tuberculosis, and mycobacterium avium. Additional diseases or conditions that can be treated using agents that activate the TLR pathway include actinic keratosis, eczema, eosinophilia, essential thrombocythaemia, leprosy, multiple sclerosis, Ommen's syndrome, discoid lupus, Bowen's disease, Bowenoid papulosis, and alopecia areata. In addition, such agents could inhibit formation
15 of Keloids and other types of post-surgical scars and enhance or stimulate the healing of wounds, including chronic wounds. The agents may be useful for treating the opportunistic infections and tumors that occur after suppression of cell mediated immunity in, for example, transplant patients, cancer patients and HIV patients.


In some embodiments, the IRM compound can be a known IRM compound
20 including the small organic IRM molecules described in detail below, or the purine derivatives, small heterocyclic compounds, amide derivatives, and oligonucleotide sequences described above. Alternatively, the IRM molecules employed in some treatment methods may include compounds subsequently identified as TLR agonists.

An amount of an IRM compound or other agent effective to activate the Toll
25 pathway and induce cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells to produce an amount of one or more cytokines such as, for example, IFN- α , TNF- α , IL-1, IL-6, IL-10 and IL-12 that is increased over the background level of such cytokines. The precise amount will vary according to factors known in the art but is expected to be a dose of
30 about 100 ng/kg to about 50 mg/kg, preferably about 10 μ g/kg to about 5 mg/kg. IRM compounds are the preferred agent for activation of the TLR pathway.

The organism treated for the disorder may be a plant or animal, particularly a vertebrate. Preferably the organism treated for the disorder is a mammal, such as, but not limited to, human, rodent, dog, cat, pig, sheep, goat, or cow.

5 IRM Compounds

Known IRM compounds of the present invention include 1*H*-imidazo[4,5-*c*]quinolin-4-amines defined by one of Formulas I-V below:



I

10 wherein


R_{11} is selected from the group consisting of alkyl of one to ten carbon atoms, hydroxyalkyl of one to six carbon atoms, acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms, benzyl, (phenyl)ethyl and phenyl, said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and halogen, with the proviso that if said benzene ring is substituted by two of said moieties, then said moieties together contain no more than six carbon atoms;

20 R_{21} is selected from the group consisting of hydrogen, alkyl of one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms and halogen, with the proviso that when the benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms;

25 and

each R_1 is independently selected from the group consisting of alkoxy of one to four carbon atoms, halogen, and alkyl of one to four carbon atoms, and n is an integer

from 0 to 2, with the proviso that if n is 2, then said R₁ groups together contain no more than six carbon atoms;




II

5 wherein

R₁₂ is selected from the group consisting of straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from the group consisting of straight chain or branched chain alkyl containing one to four carbon atoms and cycloalkyl containing three to six carbon atoms; and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; and

R₂₂ is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of straight chain or branched chain alkyl containing one to four carbon atoms, straight chain or branched chain alkoxy containing one to four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than six carbon atoms; and

each R₂ is independently selected from the group consisting of straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said R₂ groups together contain no more than six carbon atoms;




III

wherein

R_{23} is selected from the group consisting of hydrogen, straight chain or branched chain alkyl of one to eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of straight chain or branched chain alkyl of one to four carbon atoms, straight chain or branched chain alkoxy of one to four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than six carbon atoms; and

each R_3 is independently selected from the group consisting of straight chain or branched chain alkoxy of one to four carbon atoms, halogen, and straight chain or branched chain alkyl of one to four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said R_3 groups together contain no more than six carbon atoms;



IV


wherein

R_{14} is $-CHR_xR_y$ wherein R_y is hydrogen or a carbon-carbon bond, with the proviso that when R_y is hydrogen R_x is alkoxy of one to four carbon atoms, hydroxyalkoxy of one to four carbon atoms, 1-alkynyl of two to ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, 2-, 3-, or 4-pyridyl, and with the further proviso that when R_y is a carbon-carbon bond R_y and R_x together form a tetrahydrofuran group optionally substituted with one or more substituents independently selected from the group consisting of hydroxy and hydroxyalkyl of one to four carbon atoms;

R_{24} is selected from the group consisting of hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group

consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen; and

R₄ is selected from the group consisting of hydrogen, straight chain or branched chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to four carbon atoms;




V

wherein

R₁₅ is selected from the group consisting of: hydrogen; straight chain or branched chain alkyl containing one to ten carbon atoms and substituted straight chain or branched chain alkyl containing one to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; hydroxyalkyl of one to six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms; benzyl; (phenyl)ethyl; and phenyl; said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms;

R₂₅ is



wherein


R₅ and R₇ are independently selected from the group consisting of hydrogen, alkyl
 5 of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is
 selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to
 four carbon atoms, and halogen;

X is selected from the group consisting of alkoxy containing one to four carbon
 atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the
 10 alkyl moiety contains one to four carbon atoms, hydroxyalkyl of one to four carbon atoms,
 haloalkyl of one to four carbon atoms, alkylamido wherein the alkyl group contains one to
 four carbon atoms, amino, substituted amino wherein the substituent is alkyl or
 hydroxyalkyl of one to four carbon atoms, azido, chloro, hydroxy, 1-morpholino, 1-
 pyrrolidino, alkylthio of one to four carbon atoms; and

15 R₅ is selected from the group consisting of hydrogen, straight chain or branched
 chain alkoxy containing one to four carbon atoms, halogen, and straight chain or branched
 chain alkyl containing one to four carbon atoms;

and a pharmaceutically acceptable salt of any of the foregoing.

Preferred 6,7 fused cycloalkylimidazopyridine amine IRM compounds are defined
 20 by Formula VI below:



VI

wherein m is 1, 2, or 3;

R₁₆ is selected from the group consisting of hydrogen; cyclic alkyl of three, four, or
 25 five carbon atoms; straight chain or branched chain alkyl containing one to ten carbon
 atoms and substituted straight chain or branched chain alkyl containing one to ten carbon
 atoms, wherein the substituent is selected from the group consisting of cycloalkyl

containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; fluoro- or chloroalkyl containing from one to ten carbon atoms and one or more fluorine or chlorine atoms; straight chain or branched chain alkenyl containing two to ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to six carbon atoms and cycloalkyl containing three to six carbon atoms substituted by straight chain or branched chain alkyl containing one to four carbon atoms; hydroxyalkyl of one to six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to four carbon atoms or benzoyloxy, and the alkyl moiety contains one to six carbon atoms, with the proviso that any such alkyl, substituted alkyl, alkenyl, substituted alkenyl, hydroxyalkyl, alkoxyalkyl, or acyloxyalkyl group does not have a fully carbon substituted carbon atom bonded directly to the nitrogen atom; benzyl; (phenyl)ethyl; and phenyl; said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms;

and $-CHR_xR_y$

wherein

R_y is hydrogen or a carbon-carbon bond, with the proviso that when R_y is hydrogen R_x is alkoxy of one to four carbon atoms, hydroxyalkoxy of one to four carbon atoms, 1-alkynyl of two to ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, 2-, 3-, or 4-pyridyl, and with the further proviso that when R_y is a carbon-carbon bond R_y and R_x together form a tetrahydrofuran group optionally substituted with one or more substituents independently selected from the group consisting of hydroxy and hydroxyalkyl of one to four carbon atoms,

R_{26} is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to eight carbon atoms, straight chain or branched chain


hydroxyalkyl containing one to six carbon atoms, morpholinoalkyl, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by a moiety selected from the group consisting of methyl, methoxy, and halogen; and

- 5 $-C(R_S)(R_T)(X)$ wherein R_S and R_T are independently selected from the group consisting of hydrogen, alkyl of one to four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen;

- 10 X is selected from the group consisting of alkoxy containing one to four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, haloalkyl of one to four carbon atoms, alkylamido wherein the alkyl group contains one to four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to four carbon atoms, azido, alkylthio of one to four carbon atoms, and morpholinoalkyl wherein the alkyl moiety
15 contains one to four carbon atoms, and

- R_6 is selected from the group consisting of hydrogen, fluoro, chloro, straight chain or branched chain alkyl containing one to four carbon atoms, and straight chain or branched chain fluoro- or chloroalkyl containing one to four carbon atoms and at least one fluorine or chlorine atom;
20 and pharmaceutically acceptable salts thereof.

Preferred imidazopyridine amine IRM compounds are defined by Formula VII below:



VII

- 25 wherein

R_{17} is selected from the group consisting of hydrogen; $-CH_2R_W$ wherein R_W is selected from the group consisting of straight chain, branched chain, or cyclic alkyl containing one to ten carbon atoms, straight chain or branched chain alkenyl containing two to ten carbon atoms, straight chain or branched chain hydroxyalkyl containing one to

six carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms, and phenylethyl; and -CH=CR_ZR_Z wherein each R_Z is independently straight chain, branched chain, or cyclic alkyl of one to six carbon atoms;


5 R₂₇ is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to eight carbon atoms, straight chain or branched chain hydroxyalkyl containing one to six carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to six carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being
10 optionally substituted on the benzene ring by a moiety selected from the group consisting of methyl, methoxy, and halogen; and morpholinoalkyl wherein the alkyl moiety contains one to four carbon atoms;

R₆₇ and R₇₇ are independently selected from the group consisting of hydrogen and alkyl of one to five carbon atoms, with the proviso that R₆₇ and R₇₇ taken together contain
15 no more than six carbon atoms, and with the further proviso that when R₇₇ is hydrogen then R₆₇ is other than hydrogen and R₂₇ is other than hydrogen or morpholinoalkyl, and with the further proviso that when R₆₇ is hydrogen then R₇₇ and R₂₇ are other than hydrogen;

and pharmaceutically acceptable salts thereof.

20

Preferred 1,2-bridged imidazoquinoline amine IRM compounds are defined by Formula VIII below:



VIII

25 wherein

Z is selected from the group consisting of:

-(CH₂)_p- wherein p is 1 to 4;

-(CH₂)_a-C(R_DR_E)(CH₂)_b-, wherein a and b are integers and a+b is 0 to 3, R_D is hydrogen or alkyl of one to four carbon atoms, and R_E is selected from the group


consisting of alkyl of one to four carbon atoms, hydroxy, $-OR_F$ wherein R_F is alkyl of one to four carbon atoms, and $-NR_GR'_G$ wherein R_G and R'_G are independently hydrogen or alkyl of one to four carbon atoms; and

5 $-(CH_2)_a-(Y)-(CH_2)_b-$ wherein a and b are integers and $a+b$ is 0 to 3, and Y is O, S, or $-NR_J-$ wherein R_J is hydrogen or alkyl of one to four carbon atoms;

and wherein q is 0 or 1 and R_8 is selected from the group consisting of alkyl of one to four carbon atoms, alkoxy of one to four carbon atoms, and halogen,

and pharmaceutically acceptable salts thereof.

10 Suitable thiazolo- and oxazolo- quinolinamine and pyridinamine compounds include compounds of Formula IX:



IX

wherein:

R_{19} is selected from the group consisting of oxygen, sulfur and selenium;

15 R_{29} is selected from the group consisting of

- hydrogen;
- alkyl;
- alkyl-OH;
- haloalkyl;
- 20 -alkenyl;
- alkyl-X-alkyl;
- alkyl-X-alkenyl;
- alkenyl-X-alkyl;
- alkenyl-X-alkenyl;
- 25 -alkyl- $N(R_{59})_2$;
- alkyl- N_3 ;
- alkyl-O-C(O)- $N(R_{59})_2$;
- heterocyclyl;
- alkyl-X-heterocyclyl;

-alkenyl-X-heterocyclyl;

-aryl;

-alkyl-X-aryl;

-alkenyl-X-aryl;

5

-heteroaryl;

-alkyl-X-heteroaryl; and

-alkenyl-X-heteroaryl;

R_{39} and R_{49} are each independently:

-hydrogen;

10

-X-alkyl;

-halo;

-haloalkyl;

- $N(R_{59})_2$;

or when taken together, R_{39} and R_{49} form a fused

15

aromatic, heteroaromatic, cycloalkyl or heterocyclic ring;


X is selected from the group consisting of $-O-$, $-S-$, $-NR_{59}-$, $-C(O)-$, $-C(O)O-$, $-OC(O)-$, and a bond; and

each R_{59} is independently H or C_{1-8} alkyl;

and pharmaceutically acceptable salts thereof.

20

Suitable imidazonaphthyridine and tetrahydroimidazonaphthyridine IRM compounds are those of Formulae X and XI below:



X

25

wherein

A is $=N-CR=CR-CR=$; $=CR-N=CR-CR=$; $=CR-CR=N-CR=$; or $=CR-CR=CR-N=$;

R_{110} is selected from the group consisting of:

- hydrogen;


-C₁₋₂₀ alkyl or C₂₋₂₀ alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

- aryl;
- heteroaryl;
- 5 -heterocyclyl;
- O-C₁₋₂₀ alkyl,
- O-(C₁₋₂₀alkyl)₀₋₁-aryl;
- O-(C₁₋₂₀alkyl)₀₋₁-heteroaryl;
- O-(C₁₋₂₀alkyl)₀₋₁-heterocyclyl;
- 10 -C₁₋₂₀ alkoxycarbonyl;
- S(O)₀₋₂-C₁₋₂₀ alkyl;
- S(O)₀₋₂-(C₁₋₂₀ alkyl)₀₋₁-aryl;
- S(O)₀₋₂-(C₁₋₂₀ alkyl)₀₋₁-heteroaryl;
- S(O)₀₋₂-(C₁₋₂₀ alkyl)₀₋₁-heterocyclyl;
- 15 -N(R₃₁₀)₂;
- N₃;
- oxo;
- halogen;
- NO₂;
- 20 -OH; and
- SH; and

-C₁₋₂₀ alkyl-NR₃₁₀-Q-X-R₄₁₀ or -C₂₋₂₀ alkenyl-NR₃₁₀-Q-X-R₄₁₀ wherein Q is -CO- or -SO₂-; X is a bond, -O- or -NR₃₁₀- and R₄₁₀ is aryl; heteroaryl; heterocyclyl; or -C₁₋₂₀ alkyl or C₂₋₂₀ alkenyl that is unsubstituted or substituted by one or more substituents selected from the group consisting of:

- aryl;
- heteroaryl;
- heterocyclyl;
- 30 -O-C₁₋₂₀ alkyl,
- O-(C₁₋₂₀alkyl)₀₋₁-aryl;
- O-(C₁₋₂₀alkyl)₀₋₁-heteroaryl;

-O-(C₁₋₂₀alkyl)₀₋₁-heterocyclyl;
 -C₁₋₂₀ alkoxy carbonyl;
 -S(O)₀₋₂-C₁₋₂₀ alkyl;
 -S(O)₀₋₂-(C₁₋₂₀ alkyl)₀₋₁-aryl;
 5 -S(O)₀₋₂-(C₁₋₂₀ alkyl)₀₋₁-heteroaryl;
 -S(O)₀₋₂-(C₁₋₂₀ alkyl)₀₋₁-heterocyclyl;
 -N(R₃₁₀)₂;
 -NR₃₁₀-CO-O-C₁₋₂₀alkyl;
 -N₃;
 10 oxo;
 -halogen;
 -NO₂;
 -OH; and
 -SH; or R₄₁₀ is



15 wherein Y is -N- or -CR-;

R₂₁₀ is selected from the group consisting of:

-hydrogen;
 -C₁₋₁₀ alkyl;
 20 -C₂₋₁₀ alkenyl;
 -aryl;
 -C₁₋₁₀ alkyl -O-C₁₋₁₀-alkyl;
 -C₁₋₁₀ alkyl-O-C₂₋₁₀ alkenyl; and
 -C₁₋₁₀ alkyl or C₂₋₁₀ alkenyl substituted by one or more substituents selected from

25 the group consisting of:

-OH;
 -halogen;
 -N(R₃₁₀)₂;

-CO-N(R₃₁₀)₂;

-CO-C₁₋₁₀ alkyl;

-N₃;

-aryl;

5

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;


each R₃₁₀ is independently selected from the group consisting of hydrogen and C₁-

10 alkyl; and

each R is independently selected from the group consisting of hydrogen,

C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, halogen and trifluoromethyl,

and pharmaceutically acceptable salts thereof.



15

XI

wherein

B is -NR-C(R)₂-C(R)₂-C(R)₂-; -C(R)₂-NR-C(R)₂-C(R)₂-;

-C(R)₂-C(R)₂-NR-C(R)₂- or -C(R)₂-C(R)₂-C(R)₂-NR-;

R₁₁₁ is selected from the group consisting of:

20

- hydrogen;

-C₁₋₂₀ alkyl or C₂₋₂₀ alkenyl that is unsubstituted or substituted by one or more

substituents selected from the group consisting of:

-aryl;

-heteroaryl;

25

-heterocyclyl;

-O-C₁₋₂₀ alkyl;

-O-(C₁₋₂₀alkyl)₀₋₁-aryl;

-O-(C₁₋₂₀alkyl)₀₋₁-heteroaryl;

-O-(C₁₋₂₀alkyl)₀₋₁-heterocyclyl;


-C₁₋₂₀ alkoxycarbonyl;
 -S(O)₀₋₂-C₁₋₂₀ alkyl;
 -S(O)₀₋₂-(C₁₋₂₀ alkyl)₀₋₁-aryl;
 -S(O)₀₋₂-(C₁₋₂₀ alkyl)₀₋₁-heteroaryl;
 5 -S(O)₀₋₂-(C₁₋₂₀ alkyl)₀₋₁-heterocyclyl;
 -N(R₃₁₁)₂;
 -N₃;
 oxo;
 -halogen;
 10 -NO₂;
 -OH; and
 -SH; and

-C₁₋₂₀ alkyl-NR₃₁₁-Q-X-R₄₁₁ or -C₂₋₂₀ alkenyl-NR₃₁₁-Q-X-R₄₁₁ wherein Q is -CO-
 15 or -SO₂-; X is a bond, -O- or -NR₃₁₁- and R₄₁₁ is aryl; heteroaryl; heterocyclyl; or -C₁₋₂₀
 alkyl or C₂₋₂₀ alkenyl that is unsubstituted or substituted by one or more substituents
 selected from the group consisting of:

-aryl;
 -heteroaryl;
 20 -heterocyclyl;
 -O-C₁₋₂₀ alkyl,
 -O-(C₁₋₂₀alkyl)₀₋₁-aryl;
 -O-(C₁₋₂₀alkyl)₀₋₁-heteroaryl;
 -O-(C₁₋₂₀alkyl)₀₋₁-heterocyclyl;
 25 -C₁₋₂₀ alkoxycarbonyl;
 -S(O)₀₋₂-C₁₋₂₀ alkyl;
 -S(O)₀₋₂-(C₁₋₂₀ alkyl)₀₋₁-aryl;
 -S(O)₀₋₂-(C₁₋₂₀ alkyl)₀₋₁-heteroaryl;
 -S(O)₀₋₂-(C₁₋₂₀ alkyl)₀₋₁-heterocyclyl;
 30 -N(R₃₁₁)₂;
 -NR₃₁₁-CO-O-C₁₋₂₀alkyl;
 -N₃;

oxo;
 -halogen;
 -NO₂;
 -OH; and
 -SH; or R₄₁₁ is

5



wherein Y is -N- or -CR-;

R₂₁₁ is selected from the group consisting of:


-hydrogen;
 -C₁₋₁₀ alkyl;
 -C₂₋₁₀ alkenyl;
 -aryl
 -C₁₋₁₀ alkyl -O-C₁₋₁₀-alkyl;
 -C₁₋₁₀ alkyl-O-C₂₋₁₀ alkenyl; and
 -C₁₋₁₀ alkyl or C₂₋₁₀ alkenyl substituted by one or more substituents selected from
 the group consisting of:

-OH;
 -halogen;
 -N(R₃₁₁)₂;
 -CO-N(R₃₁₁)₂;
 -CO-C₁₋₁₀ alkyl;
 -N₃;
 -aryl;
 -heteroaryl;
 -heterocyclyl;
 -CO-aryl; and
 -CO-heteroaryl;

each R_{311} is independently selected from the group consisting of hydrogen and C_{1-10} alkyl; and

each R is independently selected from the group consisting of hydrogen, C_{1-10} alkyl, C_{1-10} alkoxy, halogen and trifluoromethyl, and pharmaceutically acceptable salts thereof.

Additional preferred 1*H*-imidazo[4,5-*c*]quinolin-4-amines and tetrahydro- 1*H*-imidazo[4,5-*c*]quinolin-4-amines include compounds defined by Formulas XII, XIII and XIV below:



XII

wherein

R_{112} is -alkyl- NR_{312} -CO- R_{412} or -alkenyl- NR_{312} -CO- R_{412} wherein R_{412} is aryl, heteroaryl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents selected from the group consisting of:

- alkyl;
- alkenyl;
- alkynyl;
- (alkyl)₀₋₁-aryl;
- (alkyl)₀₋₁-(substituted aryl);
- (alkyl)₀₋₁-heteroaryl;
- (alkyl)₀₋₁-(substituted heteroaryl);
- O-alkyl;
- O-(alkyl)₀₋₁-aryl;
- O-(alkyl)₀₋₁-(substituted aryl);
- O-(alkyl)₀₋₁-heteroaryl;
- O-(alkyl)₀₋₁-(substituted heteroaryl);
- CO-aryl;
- CO-(substituted aryl);

- 5
- CO-heteroaryl;
 - CO-(substituted heteroaryl);
 - COOH;
 - CO-O-alkyl;
 - CO-alkyl;
 - S(O)₀₋₂-alkyl;
 - S(O)₀₋₂-(alkyl)₀₋₁-aryl;
 - S(O)₀₋₂-(alkyl)₀₋₁-(substituted aryl);
 - S(O)₀₋₂-(alkyl)₀₋₁-heteroaryl;

10


 - S(O)₀₋₂-(alkyl)₀₋₁-(substituted heteroaryl);
 - P(O)(OR₃₁₂)₂;
 - NR₃₁₂-CO-O-alkyl;
 - N₃;
 - halogen;

15

 - NO₂;
 - CN;
 - haloalkyl;
 - O-haloalkyl;
 - CO-haloalkyl;

20

 - OH;
 - SH; and in the case of alkyl, alkenyl, or heterocyclyl, oxo;
- or R₄₁₂ is



- 25
- wherein R₅₁₂ is an aryl, (substituted aryl), heteroaryl, (substituted heteroaryl), heterocyclyl or (substituted heterocyclyl) group;

R₂₁₂ is selected from the group consisting of:

- 30
- hydrogen;
 - alkyl;
 - alkenyl;
 - aryl;

- (substituted aryl);
- heteroaryl;
- (substituted heteroaryl);
- heterocyclyl;
- 5 - (substituted heterocyclyl);
- alkyl -O-alkyl;
- alkyl-O-alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from the


group consisting of:

- 10 -OH;
- halogen;
- N(R₃₁₂)₂;
- CO-N(R₃₁₂)₂;
- CO-C₁₋₁₀ alkyl;
- 15 -CO-O-C₁₋₁₀ alkyl;
- N₃;
- aryl;
- (substituted aryl);
- heteroaryl;
- 20 - (substituted heteroaryl);
- heterocyclyl;
- (substituted heterocyclyl);
- CO-aryl; and
- CO-heteroaryl;

- 25 each R₃₁₂ is independently selected from the group consisting of hydrogen; C₁₋₁₀ alkyl-heteroaryl; C₁₋₁₀ alkyl-(substituted heteroaryl); C₁₋₁₀ alkyl-aryl; C₁₋₁₀ alkyl-(substituted aryl) and C₁₋₁₀ alkyl;

v is 0 to 4;

- 30 and each R₁₂ present is independently selected from the group consisting of C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, halogen and trifluoromethyl;



XIII

wherein

5 R_{113} is -alkyl- NR_{313} - SO_2 -X- R_{413} or -alkenyl- NR_{313} - SO_2 -X- R_{413} ;

X is a bond or $-NR_{513}-$;

R_{413} is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be unsubstituted or substituted by one or more substituents selected from the group consisting of:

- 10 -alkyl;
- alkenyl;
- aryl;
- heteroaryl;
- heterocyclyl;
- 15 -substituted cycloalkyl;
- substituted aryl;
- substituted heteroaryl;
- substituted heterocyclyl;
- O-alkyl;
- 20 -O-(alkyl)₀₋₁-aryl;
- O-(alkyl)₀₋₁-substituted aryl;
- O-(alkyl)₀₋₁-heteroaryl;
- O-(alkyl)₀₋₁-substituted heteroaryl;
- O-(alkyl)₀₋₁-heterocyclyl;
- 25 -O-(alkyl)₀₋₁-substituted heterocyclyl;
- COOH;
- CO-O-alkyl;
- CO-alkyl;
- S(O)₀₋₂-alkyl;

- S(O)₀₋₂-(alkyl)₀₋₁-aryl;
- S(O)₀₋₂-(alkyl)₀₋₁-substituted aryl;
- S(O)₀₋₂-(alkyl)₀₋₁-heteroaryl;
- S(O)₀₋₂-(alkyl)₀₋₁-substituted heteroaryl;
- 5 -S(O)₀₋₂-(alkyl)₀₋₁-heterocyclyl;
- S(O)₀₋₂-(alkyl)₀₋₁-substituted heterocyclyl;
- (alkyl)₀₋₁-NR₃₁₃R₃₁₃;
- (alkyl)₀₋₁-NR₃₁₃-CO-O-alkyl;
- (alkyl)₀₋₁-NR₃₁₃-CO-alkyl;
- 10 -(alkyl)₀₋₁-NR₃₁₃-CO-aryl;
- (alkyl)₀₋₁-NR₃₁₃-CO-substituted aryl;
- (alkyl)₀₋₁-NR₃₁₃-CO-heteroaryl;
- (alkyl)₀₋₁-NR₃₁₃-CO-substituted heteroaryl;
- N₃;
- 15 -halogen;
- haloalkyl;
- haloalkoxy;
- CO-haloalkyl;
- CO-haloalkoxy;
- 20 -NO₂;
- CN;
- OH;
- SH; and in the case of alkyl, alkenyl, or heterocyclyl, oxo;

25 **R₂₁₃** is selected from the group consisting of:

- hydrogen;
- alkyl;
- alkenyl;
- aryl;
- 30 -substituted aryl;
- heteroaryl;
- substituted heteroaryl;

- alkyl-O-alkyl;
- alkyl-O- alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from the


group consisting of:

- 5 -OH;
- halogen;
- N(R₃₁₃)₂;
- CO-N(R₃₁₃)₂;
- CO-C₁₋₁₀ alkyl;
- 10 -CO-O-C₁₋₁₀ alkyl;
- N₃;
- aryl;
- substituted aryl;
- heteroaryl;
- 15 -substituted heteroaryl;
- heterocyclyl;
- substituted heterocyclyl;
- CO-aryl;
- CO-(substituted aryl);
- 20 -CO-heteroaryl; and
- CO-(substituted heteroaryl);

each R₃₁₃ is independently selected from the group consisting of hydrogen and C₁₋₁₀ alkyl;

R₅₁₃ is selected from the group consisting of hydrogen and C₁₋₁₀ alkyl, or R₄₁₃ and R₅₁₃ can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring;

v is 0 to 4 and each R₁₃ present is independently selected from the group consisting of C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, halogen and trifluoromethyl;



XIV

wherein

5

R_{114} is -alkyl- NR_{314} -CY- NR_{514} -X- R_{414} or
-alkenyl- NR_{314} -CY- NR_{514} -X- R_{414}

wherein

Y is =O or =S;

10

X is a bond, -CO- or -SO₂-;

R_{414} is aryl, heteroaryl, heterocyclyl, alkyl or alkenyl, each of which may be
unsubstituted or substituted by one or more substituents selected from the group consisting
of:

15

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-substituted aryl;

20

-substituted heteroaryl;

-substituted heterocyclyl;

-O-alkyl;

-O-(alkyl)₀₋₁-aryl;

-O-(alkyl)₀₋₁-substituted aryl;

25

-O-(alkyl)₀₋₁-heteroaryl;

-O-(alkyl)₀₋₁-substituted heteroaryl;

-O-(alkyl)₀₋₁-heterocyclyl;

-O-(alkyl)₀₋₁-substituted heterocyclyl;

-COOH;

- CO-O-alkyl;
 - CO-alkyl;
 - S(O)₀₋₂-alkyl;
 - S(O)₀₋₂-(alkyl)₀₋₁-aryl;
 - 5 -S(O)₀₋₂-(alkyl)₀₋₁-substituted aryl;
 - S(O)₀₋₂-(alkyl)₀₋₁-heteroaryl;
 - S(O)₀₋₂-(alkyl)₀₋₁-substituted heteroaryl;
 - S(O)₀₋₂-(alkyl)₀₋₁-heterocyclyl;
 - S(O)₀₋₂-(alkyl)₀₋₁-substituted heterocyclyl;
 - 10 -(alkyl)₀₋₁-NR₃₁₄R₃₁₄;
 - (alkyl)₀₋₁-NR₃₁₄-CO-O-alkyl;
 - (alkyl)₀₋₁-NR₃₁₄-CO-alkyl;
 - (alkyl)₀₋₁-NR₃₁₄-CO-aryl;
 - (alkyl)₀₋₁-NR₃₁₄-CO-substituted aryl;
 - 15 -(alkyl)₀₋₁-NR₃₁₄-CO-heteroaryl;
 - (alkyl)₀₋₁-NR₃₁₄-CO-substituted heteroaryl;
 - N₃;
 - halogen;
 - haloalkyl;
 - 20 -haloalkoxy;
 - CO-haloalkoxy;
 - NO₂;
 - CN;
 - OH;
 - 25 -SH; and, in the case of alkyl, alkenyl or heterocyclyl, oxo;
- with the proviso that when X is a bond R₄₁₄ can additionally be hydrogen;
R₂₁₄ is selected from the group consisting of:
- hydrogen;
 - alkyl;
 - 30 -alkenyl;
 - aryl;
 - substituted aryl;

-heteroaryl;
 -substituted heteroaryl;
 -alkyl -O-alkyl;
 -alkyl-O-alkenyl; and
 5 -alkyl or alkenyl substituted by one or more substituents selected from the
 group consisting of:

-OH;
 -halogen;
 -N(R₃₁₄)₂;
 10 -CO-N(R₃₁₄)₂;
 -CO-C₁₋₁₀ alkyl;
 -CO-O-C₁₋₁₀ alkyl;
 -N₃;
 -aryl;
 15 -substituted aryl;
 -heteroaryl;
 -substituted heteroaryl;
 -heterocyclyl;
 -substituted heterocyclyl;
 20 -CO-aryl;
 -CO-(substituted aryl);
 -CO-heteroaryl; and
 -CO-(substituted heteroaryl);

each R₃₁₄ is independently selected from the group consisting of hydrogen and C₁₋₁₀ alkyl;
 25

R₅₁₄ is selected from the group consisting of hydrogen and C₁₋₁₀ alkyl, or R₄₁₄ and R₅₁₄ can combine to form a 3 to 7 membered heterocyclic or substituted heterocyclic ring;

v is 0 to 4 and each R₁₄ present is independently selected from the group consisting of C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, halogen and trifluoromethyl, and a pharmaceutically
 30 acceptable salts thereof.

.. Known IRM compounds also include the purine derivatives, small heterocyclic compounds, amide derivatives, and oligonucleotide sequences described above.

Examples

The following examples have been selected merely to further illustrate features, advantages, and other details of the invention. It is to be expressly understood, however, that while the examples serve this purpose, the particular materials and amounts used as well as other conditions and details are not to be construed in a matter that would unduly limit the scope of this invention.

Compounds

The compounds used in the following Examples and citations for methods for synthesizing each compound are provided in Table 1.

Table 1

<u>Compound</u>	<u>Chemical Name</u>	<u>Citation</u>
Imiquimod	1-(2-methylpropyl)-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolin-4-amine	U.S. 4,689,338 Example 99
Resiquimod	4-amino-2-ethoxymethyl- α,α -dimethyl-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinoline-1-ethanol	U.S. 5,389,640 Example 99
IRM 1	4-amino- $\alpha,\alpha,2$ -trimethyl-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinoline-1-ethanol hydrochloride	U.S. 5,266,575 Example C1*
IRM 2	2-propylthiazolo[4,5- <i>c</i>]quinolin-4-amine	U.S. 6,110,929 Example 12
IRM 3	N-[4-(4-amino-2-butyl)-1 <i>H</i> -imidazo[4,5- <i>c</i>][1,5]naphthyridin-1-yl)butyl]-N'-cyclohexylurea	U.S. 6,194,425 Example 48
IRM 4	1-{2-[3-(3-pyridyl)propoxy]ethyl}-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolin-4-amine	WO 02/46193 Example 33
IRM 5	2-butyl-1-(2-methylpropyl)-1 <i>H</i> -imidazo[4,5- <i>c</i>][1,8]naphthyridin-4-amine	U.S. 6,194,425 Example 12
IRM 6	2-butyl-1-(2-methylpropyl)-1 <i>H</i> -imidazo[4,5- <i>c</i>][1,7]naphthyridin-4-amine	U.S. 6,194,425 Example 27
IRM 7	2-butyl-1-(2-methylpropyl)-1 <i>H</i> -imidazo[4,5- <i>c</i>][1,5]naphthyridin-4-amine	U.S. 6,194,425 Example 39
IRM 8	2-butyl-6,7,8,9-tetrahydro-1-(2-methylpropyl)-1 <i>H</i> -imidazo[4,5- <i>c</i>][1,5]naphthyridin-4-amine	U.S. 6,194,425 Example 40

<u>Compound</u>	<u>Chemical Name</u>	<u>Citation</u>
IRM 9	4-amino-2-ethoxymethyl- α,α -dimethyl-6,7,8,9-tetrahydro-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinoline-1-ethanol	U.S. 5,352,784 Example 91
IRM 10	1-[<i>R</i> (+)-1-phenylethyl]-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolin-4-amine	U.S. 4,689,338 Example 185**
IRM 11	2-butyl[1,3]thiazolo[4,5- <i>c</i>][1,5]naphthyridin-4-amine	U.S. 6,110,929 Example 58
IRM 12	N-[4-(4-amino-2-butyl-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolin-1-yl)butyl]methanesulfonamide	U.S. 6,331,539 Example 6
IRM 13	8,9,10,11-tetrahydropyrido[1',2':1,2]imidazo[4,5- <i>c</i>]quinolin-6-amine	U.S. 5,482,936 Example 1
IRM 14	N ³ -(4-[4-amino-2-(2-methoxyethyl)-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolin-1-yl]butyl)-6-(1 <i>H</i> -1-pyrrolyl)nicotinamide	U.S. 6,451,810 Example 60
IRM 15	N-[2-(4-amino-2-butyl-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolin-1-yl)ethyl]methanesulfonamide	U.S. 6,331,539 Example 34***
IRM 16	N-{4-[4-amino-2-(2-methoxyethyl)-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolin-1-yl]butyl}morpholine-4-carboxamide	WO 00/76518 Example 121***
IRM 17	N-[4-(4-amino-2-butyl-6,7-dimethyl-1 <i>H</i> -imidazo[4,5- <i>c</i>]pyridin-1-yl)butyl]methanesulfonamide	WO 02/46194 Example 2
IRM 18	2-ethyl-1-[5-(methylsulfonyl)pentyl]-1 <i>H</i> -imidazo[4,5- <i>c</i>]quinolin-4-amine	WO 02/46192 Example 13

*Example C1 is the free base. The hydrochloride salt is prepared using conventional methods.

**Example 185 is the racemic mixture. The chiral compound is prepared using (*R*)-(+)- α -methylbenzylamine (available from Aldrich, Milwaukee, WI, USA).

5 ***Examples 34 and 121 are trifluoroacetate salts. The salt is converted to the free base using conventional methods.

Cells

10 **HEK293 cells** - immortalized human embryonic kidney cells, available from American Type Culture Collection, Manassas, VA, ATCC No. CRL-1573.

RAW 264.7 cells - mouse macrophage cells, available from American Type Tissue Collection, Manassas, VA, ATCC No. TIB-71.

THP-1 cells - human monocyte cells derived from acute monocytic leukemia tissue; available from American Type Culture Collection, Manassas, VA, ATCC No. TIB-202.

5 **Cell Culture Media**

Complete RPMI was prepared by mixing RPMI 1640 with 25mM HEPES, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, and 1 mM L-glutamine (Celox Laboratories, Inc., Minneapolis, MN) supplemented with 10% heat inactivated fetal calf serum (FCS) (Hyclone Laboratories, Inc., Logan, UT) and 1% penicillin/streptomycin
10 (Sigma Chemical Co., St. Louis, MO). For the transfection of dominant negative constructs into THP-1 cells, cRPMI was modified by the addition of 3.5 g/L glucose and 5×10^{-5} M 2-mercaptoethanol (tRPMI). For the transfection of dominant negative constructs into RAW 264.7 cells, cRPMI was modified by the addition of 5×10^{-5} M 2-mercaptoethanol (rRPMI).

15

Example 1 - The Effect of Dominant Negative TLR 6 and TLR 7

A murine TLR6 dominant negative construct was generated by PCR mutation during amplification from RAW 264.7 cell cDNA. The 5' and 3' regions flanking a codon encoding proline 691 were amplified with primers (5' sense: SEQ ID NO 1; 5' antisense:
20 SEQ ID NO 2; 3'sense: SEQ ID NO 3; 3' antisense: SEQ ID NO 4) that changed the codon for proline 691 to a codon encoding histidine while introducing a unique Apa LI restriction enzyme site at the position of the mutation. The 5' and 3' sections of the TLR6 were amplified by Pfu Turbo DNA polymerase kit (Stratagene, La Jolla, CA). The PCR sections were inserted into pCR-Blunt II-TOPO for sequence verification. The two
25 sections were joined together when subcloned into pIRES (Clontech, Palo Alto, CA) for expression in mammalian cells.

The human TLR6 dominant negative construct was generated from human PBMC cDNA using the same strategy as the murine TLR6 dominant negative. The proline to histidine mutation for human TLR6 was introduced at amino acid 680 along with an Apa
30 LI restriction enzyme site (5' sense: SEQ ID NO 5; 5' antisense: SEQ ID NO 6; 3' sense: SEQ ID NO 7; 3' antisense: SEQ ID NO 8).

The human TLR7 dominant negative construct was generated in a manner similar to that used to generate the human TLR6 dominant negative construct. The proline to histidine mutation for human was introduced at amino acid 932 along with a Bam HI restriction enzyme site (5' sense: SEQ ID NO 9; 5' antisense: SEQ ID NO 10; 3' sense: SEQ ID NO 11; 3' antisense: SEQ ID NO 12).

The amplified 5' and 3' sections of each human dominant negative TLR was inserted into pCR-Blunt II-TOPO for sequence verification. The 5' and 3' sections were joined together when subcloned into pIRES (Clontech, Palo Alto, CA) for expression in mammalian cells.

THP-1 cells (maintained at cell number less than 1×10^6 cells/ml) were co-transfected with the plasmid vector containing either the TLR6DN or TLR7DN construct and with a murine H_2K^k plasmid (Miltenyi Biotec Inc., Auburn, CA) in a 4:1 ratio of TLR plasmid to H_2K^k plasmid. Transfection of THP-1 cells was carried out using the transfection reagent FuGENE 6 (Roche Diagnostics Corp., Indianapolis, IN) according to the manufacturer's specifications. At 18 hours post-transfection, transfected cells were selected on the basis of murine H_2K^k (Miltenyi Biotec Inc., Auburn, CA) according to the manufacturer's specifications.

RAW 264.7 cells were co-transfected with a truncated human CD4 for RAW 264.7 cells in a 4:1 ratio of TLR plasmid to CD4 plasmid. Transfection of RAW 264.7 cells was carried out using the transfection reagent DoTaP (Roche Diagnostics Corp., Indianapolis, IN) according to the manufacturer's specifications. At 18 hours post-transfection, transfected cells were selected on the basis of CD4 expression (Miltenyi Biotec Inc., Auburn, CA) for the RAW 264.7 cells according to the manufacturer's specifications.

After selection, cells were resuspended in tRPMI at a concentration of 10^6 cells/ml. 100 μ l of cells (10^5 cells) were then added to individual wells of a 96 well U-bottom plate (BD Biosciences Discovery Labware, Bedford, MA). The IRM compound was diluted to 6 μ M, LPS (Sigma Chemical Co., St. Louis, Mo.) diluted to 200 ng/ml; and zymosan (Sigma Chemical Co., St. Louis, Mo.) was diluted to 6×10^5 particles/ml. After the addition of the compound solution, cells were incubated for 18 hours at 37° C in an atmosphere of 5% CO₂/95% air. Supernatants were collected and frozen at -20° C for cytokine analysis.

TNF- α levels were measured with a commercial Human TNF- α ELISA kit (Biosource International, Inc., Camarillo, CA) according to the manufacturer's specifications. Results are presented in % inhibition over vector control.

The data in Table 1 represent results of THP-1 cells transfected with either TLR6DN or TLR7DN, stimulated for 18 hours with 3 μ M resiquimod, 100 ng LPS, or 3x 10⁵ particles of zymosan. Results are presented in % inhibition relative to vector control. Data shown are representative of six independent experiments.

Table 2 - TNF- α Production by THP-1 Cells Transfected with Either TLR6DN or TLR7DN

<u>Stimulus</u>	<u>TLR6DN</u>		<u>TLR7DN</u>	
	<u>% inhibition</u>	<u>SEM</u>	<u>% inhibition</u>	<u>SEM</u>
LPS 100 ng/ml	2.5	5.4	13.2	6.1
Zymosan 3 X10 ⁵ particles/ml	58.2	4.2	6.9	3.2
Resiquimod 3 μ M	70.1	1.3	55.3	2.4

Table 3 - TNF- α Production by RAW 264.7 Cells Transfected with TLR6DN

<u>Stimulus</u>	<u>% inhibition</u>	<u>SEM</u>
LPS 100 ng/ml	17.6	1.2
Zymosan 3 X10 ⁵ particles/ml	80.7	3.9
Resiquimod 3 μ M	70.9	3.6

Example 2 Antibody Blocking of IRM-Mediated Cell Stimulation

Rabbit polyclonal antibodies were generated by Quality Controlled Biochemicals, Inc., (Hopkinton, MA). Antibody specificity was verified by flow cytometry and western blotting.

Peripheral blood mononuclear cells (PBMCs) were isolated with the Histopaque HybriMax -1077 density gradient (Sigma Chemical Co., St. Louis, MO) from healthy human volunteers after obtaining informed consent.

PBMC were resuspended in cRPMI at a concentration of 10⁶ cells/ml. 100 μ l of cells (10⁵ cells) were then added to individual wells of a 96 well U-bottom plate (BD Biosciences Discovery Labware, Bedford, MA). Solutions containing cRPMI with 40

µg/ml of the affinity purified anti-TLR6 polyclonal antibody were prepared. 50 µl of the antibody solution was added to cells and incubated for 30 minutes. The IRM compounds were diluted to 12 µM; LPS (Sigma Chemical Co., St. Louis, Mo.) was diluted to 400 ng/ml; zymosan (Sigma Chemical Co., St. Louis, Mo.) was diluted to 12×10^5 particles/ml; and peptidoglycan (Sigma Chemical Co., St. Louis, Mo.) was diluted to 40 µg/ml in cRPMI. 50 µl of the compound solution was added to cells so that the final concentration of antibody was 10 µg/ml, the final concentration of resiquimod was 3 µM, LPS was 100 ng/ml, and peptidoglycan was 10 µg/ml. Cells were incubated for 18 hours at 37° C in an atmosphere of 5% CO₂/95% air. Supernatants were collected and frozen at -20° C for cytokine analysis. The data are presented as % inhibition relative to control.

$$\% \text{ inhibition} = 100 \times \frac{(\text{control value} - \text{treated value})}{\text{control value}}$$

The IRM compounds used in this section were synthesized at 3M, St. Paul, MN. The syntheses of these compounds are described in U.S. Patent Nos. 5,389,640: Example 99 (resiquimod); 4,689,338: Example 99 (imiquimod); 5,266,575: Example C1 (Compound 1); 6,194,425: Example 48 (Compound 3); 6,110,929: Example 12 (Compound 2); 6,194,425: Example 12 (Compound 5), Example 27 (Compound 6), Example 39 (Compound 7), and Example 40 (Compound 8).

The data in Table 3 represent results of TLR6 neutralizing antibody studies in human PBMC. PBMC were stimulated for 18 hrs with 100 ng/ml LPS, 10 µg/ml peptidoglycan, zymosan particles, or the indicated concentration of IRM compound. Results are presented in % inhibition relative to media control. Data shown are representative of six independent experiments.

**Table 4 - Anti-TLR6 Antibody Inhibition of TNF- α Production
by Human PBMC Cells**

Stimulus	% inhibition relative to control (no Ab)	SEM
100 ng/ml LPS	-9.4	3.1
10 μ g/ml Peptidoglycan	50.0	7.2
Zymosan 3x10 ⁵ particles/ml	66.1	1.8
3 μ M Resiquimod	88.4	4.4
3 μ M IRM 1	70.2	3.7
3 μ M IRM 3	65.0	12.1
3 μ M IRM 2	81.0	9.3
0.12 μ M IRM 4	76.7	2.4
3 μ M IRM 5	84.2	8.7
1 μ M IRM 6	90.3	1.8
0.37 μ M IRM 7	78.2	8.4
1 μ M IRM 8	64.7	1

Example 3 - Overexpression of Wild-Type TLR 6 or TLR 7

5 The murine TLR wild-type vectors were generated by PCR amplification from RAW 264.7 cell cDNA with TLR6 specific primers (sense primer: SEQ ID NO 13; antisense primer: SEQ ID NO 14) or TLR7 specific primers (sense primer: SEQ ID NO 15; antisense primer: SEQ ID NO 16) by Pfu Turbo DNA polymerase kit (Stratagene, La Jolla, CA). The PCR products were inserted into pCR-Blunt II-TOPO for sequence
10 verification and then subcloned into pIRES (BD Biosciences Clontech, Palo Alto, CA) for expression in mammalian cells.

 THP-1 cells or RAW 264.7 cells were cultured and transfected with the wild type TLR 6 or wild type TLR 7 plasmids described above. The transfections were performed as in Example 1 with a 4:1 ratio of wild-type TLR to H2K plasmid (THP-1 cells) or CD4
15 (RAW 264.7 cells).

 RAW 264.7 cells were stimulated with various concentrations of resiquimod and analyzed as described in Example 1. Results are provided in Table 4 and are expressed as fold increase in TNF- α production as compared to control transfected RAW 264.7 cells.

**Table 5 - IRM-Stimulated TNF- α Production by RAW 264.7
Cells Overexpressing TLR6 or TLR7**

<u>Resiquimod (μM)</u>	<u>Fold increase in TNF-α production over control</u>	
	<u>TLR 6</u>	<u>TLR 7</u>
	-	-
0.0004	9.6	14.8
0.001	8.0	8.9
0.004	9.2	5.8
0.012	3.5	3.8
0.037	3.9	3.5
1	1.4	1.3
3	1.7	1.0
10	1.8	1.5

Example 4 - Overexpression of TLR7 in HEK293 cells

5 HEK 293 cells were cultured in Minimum Essential Medium (MEM) with 2 mM L-glutamine and Earle's Balanced Salt Solution (Invitrogen Corp., Rockville, MD) adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate, 90%; heat-inactivated fetal calf serum, 10%. The cells were incubated at 37°C, 8% CO₂.

10 Twenty-four hours before transfection, HEK 293 cells were adhered to a 10 cm dish (Corning 430167, Corning Inc., Corning, NY) at 37°C, 8% CO₂. The cells were co-transfected with human TLR7 or Empty Vector control pIRES (BD Biosciences Clontech, Palo Alto, CA) along with NF κ B-luc reporter (Stratagene, La Jolla, CA) in a 10:1 ratio with Fugene 6 transfection reagent (Roche Diagnostics Corp., Indianapolis, IN) following
15 the manufacturer's instructions. The plates were incubated for 24 hours following transfection and then selected in G-418 (400ug/mL) for 2 weeks. The G-418 resistant cells containing either the TLR7 or empty vector were expanded in HEK 293 media supplemented with G-418 for stimulation experiments.

TLR7 or empty vector cells were plated in white opaque 96 well plates (Costar 3917, Corning Inc., Corning, NY) at a concentration of 5×10^4 cells per well in 100 μ L of HEK 293 media and incubated at 37°C, 8% CO₂ for 4 hours. The cells were stimulated with 1 μ L of IRM compounds at 1mM in DMSO (final concentration of 10 μ M) or 1 μ L DMSO as a control. The plates were then incubated an additional 16 hours at 37°C, 5% CO₂. The luciferase signal was read using the LucLite kit (Packard Instrument Co., Meriden, CT). The luminescence was measured on the Topcount NXT (Packard Instrument Co., Meriden, CT).

Table 6

<u>Stimulus</u>	<u>Fold Increase Over DMSO Control</u>	
	HEK 293 Vector	HEK293 TLR7
Imiquimod	1.41	17.80
IRM 9	0.81	4.67
IRM 10	1.10	2.55
IRM 11	1.35	1.06
IRM 2	1.27	0.94
IRM 1	0.86	3.75
IRM 12	1.33	15.33
IRM 4	1.00	4.06
IRM 5	1.21	1.13
IRM 6	0.95	1.25
IRM 7	1.30	3.06
IRM 8	0.91	4.59
IRM 13	1.20	2.39
IRM 14	1.31	1.37
IRM 15	1.04	1.88
IRM 16	0.98	1.51
IRM 17	0.99	2.79
IRM 17	1.67	2.71
DMSO	1.00	1.00

Various modifications and alterations to this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention. Illustrative embodiments and examples are provided as examples only and are not intended to limit the scope of the present invention. The scope of the invention is limited only by the claims set forth as follows.

5

What is Claimed is:

1. A method of eliciting a TLR6-mediated cellular response in a cell that expresses TLR6 comprising:
 - 5 selecting a compound identified as a TLR6 agonist; and
administering to the cell the compound in an amount that affects at least one TLR6-mediated cellular signaling pathway.
- 10 2. The method of claim 1 wherein the compound comprises an imidazopyridine amine, an imidazonaphthyridine amine, an imidazotetrahydronaphthyridine amine, a thiazoloquinoline amine, an oxazoloquinoline amine, a 1,2-bridged imidazoquinoline amine, a thiazolonaphthyridine amine, an imidazothienopyridine, a sulfonamido-substituted imidazoquinoline amine, a urea-substituted imidazoquinoline amine, a heteroaryl ether-substituted imidazoquinoline amine, *N*-[4-(4-amino-2-ethyl-1*H*-
15 imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide, or 4-amino-2-(ethoxymethyl)- α,α -dimethyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-1-ethanol hydrate..
- 20 3. The method of claim 1 wherein the cell is a monocyte, a macrophage, a dendritic cell, a B lymphocyte, or a cell derived from any of the foregoing.
4. The method of claim 1 wherein the cellular response comprises NF- κ B activation, IRAK phosphorylation, IRAK degradation, or the production of one or more co-stimulatory markers.
- 25 5. The method of claim 1 wherein the cellular response comprises production of IFN- α , TNF- α , IL-1, IL-6, IL-8, IL-10, IL-12, MIP-1, MCP-1, or any combination thereof.
6. A method of eliciting a TLR7-mediated cellular response in a cell that expresses TLR7 comprising:

selecting a compound identified as a TLR7 agonist; and

administering to the cell the compound in an amount that affects at least one TLR7-mediated cellular signaling pathway.

- 5 7. The method of claim 6 wherein the compound comprises an imidazopyridine amine, an imidazonaphthyridine amine, an imidazotetrahydronaphthyridine amine, a thiazoloquinoline amine, an oxazoloquinoline amine, a 1,2-bridged imidazoquinoline amine, a thiazolonaphthyridine amine, an imidazothienopyridine, a sulfonamido-substituted imidazoquinoline amine, a urea-substituted imidazoquinoline amine, a
10 heteroaryl ether-substituted imidazoquinoline amine, *N*-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide, or 4-amino-2-(ethoxymethyl)- α,α -dimethyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-1-ethanol hydrate.
- 15 8. The method of claim 6 wherein the cell is a monocyte, a macrophage, a dendritic cell, a B lymphocyte, or a cell derived from any of the foregoing.
9. The method of claim 6 wherein the administration of the compound results in the formation of a cellular complex comprising:
- 20 the IRM compound;
- TLR7; and
- one or more of IRAK, TRAF6, MyD88, or a fragment of any of the foregoing.
10. The method of claim 6 wherein the cellular response comprises NF- κ B activation, IRAK phosphorylation, IRAK degradation, or the production of one or more co-
25 stimulatory markers.
11. The method of claim 6 wherein the cellular response comprises production of TNF- α , IL-1, IL-6, IL-8, IL-10, IL-12, MIP-1, MCP-1, or any combination thereof.

12. A method of treating an organism having a condition treatable by modulating a TLR6-mediated cellular response comprising:

selecting a compound identified as a TLR6 agonist; and

5 administering to the organism the compound in an amount effective to modulate a TLR6-mediated cellular signaling pathway.

13. The method of claim 12 wherein the compound comprises an imidazopyridine amine, an imidazonaphthyridine amine, an imidazotetrahydronaphthyridine amine, a
10 thiazoloquinoline amine, an oxazoloquinoline amine, a 1,2-bridged imidazoquinoline amine, a thiazolonaphthyridine amine, an imidazothienopyridine, a sulfonamido-substituted imidazoquinoline amine, a urea-substituted imidazoquinoline amine, a heteroaryl ether-substituted imidazoquinoline amine, *N*-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide, or 4-amino-2-(ethoxymethyl)-
15 α,α -dimethyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-1-ethanol hydrate.

14. The method of claim 12 wherein the organism is a mammal.

15. The method of claim 14 wherein the mammal is a human.

20

16. The method of claim 15 wherein the condition is a neoplastic disease.

17. The method of claim 15 wherein the condition is a Th2-mediated disease.

25

18. The method of claim 17 wherein the condition is asthma, atopic dermatitis, or allergic rhinitis.

19. The method of claim 15 wherein the condition is a viral disease, a bacterial disease, a parasitic disease, a protozoal disease, or a prion-mediated disease.
20. The method of claim 12 wherein administering the IRM compound modulates at least one of: production of at least one cytokine, NF- κ B activity, and production of at least one co-stimulatory marker.
21. The method of claim 20 wherein the cytokine is TNF- α , IL-1, IL-6, IL-8, IL-10, IL-12, MIP-1, MCP-1, or any combination thereof.
22. The method of claim 20 wherein the co-stimulatory marker is CD40, CD80, CD86, CCR7, or any combination thereof.
23. A method of treating an organism having a condition treatable by modulating a TLR7-mediated cellular response comprising:
- selecting a compound identified as a TLR7 agonist; and
 - administering to the organism the compound in an amount effective to modulate a TLR7-mediated cellular signaling pathway.
24. The method of claim 23 wherein the compound comprises an imidazopyridine amine, an imidazonaphthyridine amine, an imidazotetrahydronaphthyridine amine, a thiazoloquinoline amine, an oxazoloquinoline amine, a 1,2-bridged imidazoquinoline amine, a thiazolonaphthyridine amine, an imidazothienopyridine, a sulfonamido-substituted imidazoquinoline amine, a urea-substituted imidazoquinoline amine, a heteroaryl ether-substituted imidazoquinoline amine, *N*-[4-(4-amino-2-ethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]methanesulfonamide, or 4-amino-2-(ethoxymethyl)- α,α -dimethyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-1-ethanol hydrate.

25. The method of claim 23 wherein the organism is a mammal.
26. The method of claim 25 wherein the mammal is a human.
- 5 27. The method of claim 26 wherein the condition is a neoplastic disease.
28. The method of claim 26 wherein the condition is a Th2-mediated disease.
29. The method of claim 28 wherein the condition is asthma, atopic dermatitis, or
10 allergic rhinitis.
30. The method of claim 26 wherein the condition is a viral disease, a bacterial disease, a parasitic disease, a protozoal disease, or a prion-mediated disease.
- 15 31. The method of claim 23 wherein administering the IRM modulates at least one of: production of at least one cytokine, NF- κ B activity, and production of at least one co-stimulatory marker.
32. The method of claim 31 wherein the cytokine is TNF- α , IL-1, IL-6, IL-8, IL-10,
20 IL-12, MIP-1, MCP-1, or any combination thereof.
33. The method of claim 31 wherein the co-stimulatory marker is CD40, CD80, CD86, CCR7, or any combination thereof.
- 25 34. A method of identifying an IRM compound that activates a TLR-mediated cellular signaling pathway comprising:

a) exposing a TLR-positive cell culture to a test compound and measuring a TLR-mediated cellular response;

b) exposing a TLR-negative cell culture to a test compound and measuring a TLR-mediated cellular response; and

5 c) identifying the test compound as an IRM if the cellular response in the TLR-positive cell culture is greater than the cellular response of the TLR-negative cell culture.

35. The method of claim 34 wherein the TLR-negative cell culture comprises cells that express a dominant negative variant of the TLR.

10

36. The method of claim 34 wherein the TLR-negative cell culture comprises antibodies raised against the TLR.

15

37. The method of claim 34 wherein the TLR-positive cell culture comprises cells that overexpress the TLR.

38. The method of claim 34 wherein the test compound is identified as an IRM compound if the cellular response of the TLR-positive cell culture is at least 20% greater than the cellular response of the TLR-negative cell culture.

20

39. The method of claim 34 wherein the test compound is identified as an IRM compound if the cellular response of the TLR-positive cell culture is at least 50% greater than the cellular response of the TLR-negative cell culture.

25

40. The method of claim 34 wherein the test compound is identified as an IRM compound if the cellular response of the TLR-positive cell culture is at least 80% greater than the cellular response of the TLR-negative cell culture.

41. The method of claim 34 wherein the TLR-mediated cellular response comprises NF- κ B activation.
- 5 42. The method of claim 34 wherein the TLR-mediated cellular response comprises production of at least one cytokine.
43. The method of claim 42 wherein the cytokine is TNF- α , IFN- α , IL-1, IL-6, IL-8, IL-10, IL-12, MIP-1, MCP-1, or any combination thereof.
- 10 44. The method of claim 42 wherein the IRM-responsive cell culture comprises at least one RAW 264.7 cell and the cytokine is TNF- α .
45. A compound identified as an IRM compound by the method of claim 44, and any salts thereof.
- 15 46. A pharmaceutical composition comprising a compound identified as an IRM compound by the method of claim 44 in combination with a pharmaceutically acceptable carrier.
- 20 47. A compound identified as an IRM compound by the method of claim 34, and any salts thereof.
48. A pharmaceutical composition comprising a compound identified as an IRM compound by the method of claim 34 in combination with a pharmaceutically acceptable carrier.
- 25 49. A method of identifying an IRM antagonist that inhibits a TLR-mediated cellular signaling pathway comprising:

a) exposing a first IRM-responsive cell culture to an IRM compound and measuring a TLR-mediated cellular response;

b) exposing a second IRM-responsive cell culture to an IRM compound and a test compound, and measuring a TLR-mediated cellular response; and

5 c) identifying the test compound as an IRM antagonist if the cellular response in the first cell culture is greater than the cellular response of the second cell culture.

50. The method of claim 49 wherein the IRM compound is an imidazoquinoline amine, an imidazopyridine amine, a 6,7-fused cycloalkylimidazopyridine amine, an
10 imidazonaphthyridine amine, an imidazotetrahydronaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, a 1,2-bridged imidazoquinoline amine, a thiazolonaphthyridine amine, or an imidazothienopyridine.

51. A compound identified as an IRM antagonist by the method of claim 49, and any
15 salts thereof.

52. A pharmaceutical composition comprising a compound identified as an IRM antagonist by the method of claim 49 in combination with a pharmaceutically acceptable carrier.
20

53. The use of a dominant-negative variant of a TLR to identify a compound that activates a TLR-mediated cellular signaling pathway.

54. The use of claim 53 wherein the TLR is TLR6 and the TLR-mediated cellular
25 signaling pathway is a TLR6-mediated cellular signaling pathway.

55. The use of claim 53 wherein the TLR is TLR7 and the TLR-mediated cellular signaling pathway is a TLR7-mediated cellular signaling pathway.

56. The use of an IRM compound as a positive control in an assay detecting activation of at least one TLR.

5 57. The use of claim 56 wherein the IRM comprises is an imidazoquinoline amine, an imidazopyridine amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, an imidazotetrahydronaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, a 1,2-bridged imidazoquinoline amine, a thiazolonaphthyridine amine, or an imidazothienopyridine.

10 58. The use of claim 57 wherein the IRM compound is 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine or 4-amino-2-ethoxymethyl- α,α -dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol.

15 59. The use of claim 56 wherein the TLR is TLR6 or TLR7.

Sequence Listing

<110> Gorden, Keith
Qiu, Xiaohong
Tomai, Mark
Vasilakos, John

<120> Methods and Compositions related to IRM Compounds and Toll-Like Receptor Pathways

<130> 7074US010

<140>

<141> [2002-11-14]

<150> 60/332,412

<151> 2001-11-16

<160> 16

<210> 1

<211> 28

<212> DNA

<213> Mus musculus

<400> 1

ctcgagatgg taaagtcct ctgggata

<210> 2

<211> 25

<212> DNA

<213> Mus musculus

<400> 2

gtgcacaaag ttcctctcat ggagg

<210> 3

<211> 27

<212> DNA

<213> Mus musculus

<400> 3

gtgcacggca agagcattgt ggagaac

<210> 4
<211> 29
<212> DNA
<213> Mus musculus

<400> 4
acgcgttcac atcatcctca ttgactaag

<210> 5
<211> 29
<212> DNA
<213> Homo sapiens

<400> 5
gcgcgctagc atgaccaaag acaaagaac

<210> 6
<211> 30
<212> DNA
<213> Homo sapiens

<400> 6
gcgcgcgtgc acaaagttcc tctcatgaag

<210> 7
<211> 33
<212> DNA
<213> Homo sapiens

<400> 7
gcgcgcgtgc acggcaagag cattgtggaa aat

<210> 8
<211> 29
<212> DNA
<213> Homo sapiens

<400> 8
acgcgttaag atttcacatc attgttttc

<210> 9

<211> 30
<212> DNA
<213> Homo sapiens

<400> 9
gcgcgctagc atggtgtttc caatgtggac

<210> 10
<211> 24
<212> DNA
<213> Homo sapiens

<400> 10
ggatccagtc cctttcctcg agac

<210> 11
<211> 30
<212> DNA
<213> Homo sapiens

<400> 11
gcgcacgcgt ctagaccgtt tccttgaaca

<210> 13
<211> 28
<212> DNA
<213> Mus musculus

<400> 13
ctcgagatgg taaagtcctt ctgggata

<210> 14
<211> 29
<212> DNA
<213> Mus musculus

<400> 14
acgcgttcac atcatcctca ttgactaag

<210> 15
<211> 30
<212> DNA

<213> Mus musculus

<400> 15

cgcgctagca tgggtgttttc gatgtggaca

<210> 16

<211> 30

<212> DNA

<213> Mus musculus

<400> 16

cgacgcgtgc tagactgttt ccttgaacat

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 May 2003 (30.05.2003)

PCT

(10) International Publication Number
WO 03/043572 A3

(51) International Patent Classification⁷: A61F 13/02

(21) International Application Number: PCT/US02/36758

(22) International Filing Date:
14 November 2002 (14.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/332,412 16 November 2001 (16.11.2001) US

(71) Applicant: 3M INNOVATIVE PROPERTIES COMPANY [US/US]; 3M Center, Post Office Box 33427, Saint Paul, MN 55133-3427 (US).

(72) Inventors: GORDEN, Keith, B.; Post Office Box 33427, Saint Paul, MN 55133-3427 (US). QIU, Xiaohong; Post Office Box 33427, Saint Paul, MN 55133-3427 (US). TOMAI, Mark, A.; Post Office Box 33427, Saint Paul, MN 55133-3427 (US). VASILAKOS, John, P.; Post Office Box 33427, Saint Paul, MN 55133-3427 (US).

(74) Agents: GRAM, Christopher, D. et al.; Office of Intellectual Property Counsel, Post Office Box 33427, Saint Paul, MN 55133-3427 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
24 July 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/043572 A3

(54) Title: METHODS AND COMPOSITIONS RELATED TO IRM COMPOUNDS AND TOLL-LIKE RECEPTOR PATHWAYS

(57) Abstract: Methods for identifying a compound that activates a TLR-mediated cellular signaling pathway is disclosed. The method includes (a) exposing a TLR-positive cell culture to a test compound and measuring a TLR-mediated cellular response; (b) exposing a TLR-negative cell culture to a test compound and measuring a TLR-mediated cellular response; and (c) identifying the test compound as an IRM if the cellular response in the TLR-positive cell culture is greater than the cellular response of the TLR-negative cell culture. Methods of eliciting a TLR-mediated cellular response are also disclosed. Such methods include administration of an IRM compound to an IRM-responsive cell so that the IRM compounds affects at least one TLR-mediate cellular signaling pathway.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/36758

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61F 13/02

US CL : 424/434, 435, 443

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/434, 435, 443

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BULUT et al. Cooperation of Toll-Like Receptor 2 and 6 for Cellular Activation by Soluble Tuberculosis Factor and Borrelia burgdorferi Outer Surface Protein A Lipoprotein. Journal of Immunology. July 2001, Vol. 167, No. 2, pages 987-994, especially page 990.	1-5, 12-22, 34-43, 49, 53, 54, 56, 59
Y	KODAWSKI et al. Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial Antigens. Journal of Experimental Medicine. September, 2001, Vol. 194, No. 6, pages 863-869, especially page 866.	6-11, 23-33, 34-43, 49, 53, 55, 56, 59
X --- Y	US 6,039,969 (TOMAI et al) 21 March 2000 (21.03.2000), column 1, lines 21-62, column 15, lines 31-65.	45-48, 51-52 ----- 1-33



Further documents are listed in the continuation of Box C.



See patent family annex.

Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent family

Date of the actual completion of the international search

21 February 2003 (21.02.2003)

Date of mailing of the international search report

30 MAY 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Janet Andres

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

PCT/US02/36758

Continuation of B. FIELDS SEARCHED Item 3:
STN, EAST
search terms: TLR-6, TLR-7, imidazopyridine amine